-DOCSTART- O

For	O
the	O
marc	O
assays	O
,	O
marc	O
was	O
ground	O
to	O
a	O
fine	O
powder	O
using	O
a	O
Retsch	B-BRAND
MM	I-BRAND
200	I-BRAND
Mixer	I-BRAND
Mill	I-BRAND
(	O
Retsch	B-COM
GmbH	I-COM
,	O
Haan	O
,	O
Germany	O
)	O
and	O
was	O
substituted	O
at	O
the	O
same	O
mass	O
percentage	O
(	O
35	O
%	O
total	O
diet	O
DW	O
)	O
for	O
the	O
cellulose	O
in	O
the	O
diet	O
.	O

Inhibition	O
of	O
cell	O
proliferation	O
by	O
TQ	O
was	O
evaluated	O
6	O
h	O
post-treatment	O
using	O
a	O
colorimetric	O
WST-1	O
(	O
4	O
-	O
[	O
3	O
-	O
(	O
4-iodophenyl	O
)	O
-2	O
-	O
(	O
4-nitrophenyl	O
)	O
-2	O
H-5-tetrazolio	O
]-	O
-1,3-benzenedisulfonate	O
)	O
cell	O
proliferation	O
assay	O
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

The	O
assay	O
measures	O
the	O
ability	O
of	O
viable	O
cells	O
to	O
cleave	O
,	O
by	O
mitochondrial	O
dehydrogenases	O
,	O
the	O
WST-1	O
tetrazolium	O
salt	O
to	O
formazan	O
.	O

All	O
other	O
parameters	O
were	O
analyzed	O
by	O
Labcon	B-COM
GmbH	I-COM
(	O
Vienna	O
,	O
Austria	O
)	O
using	O
validated	O
assays	O
:	O
ASSERACHROM	B-BRAND
®	I-BRAND
b-TG	I-BRAND
test	I-BRAND
kit	I-BRAND
(	O
Diagnostica	B-COM
Stago	I-COM
,	O
Asniéres	O
,	O
France	O
)	O
for	O
b-TG	O
assessment	O
,	O
TAT	O
was	O
assessed	O
using	O
the	O
Enzygnost	B-BRAND
®	I-BRAND
TAT	I-BRAND
micro	I-BRAND
kit	I-BRAND
(	O
Siemens	B-COM
GmbH	I-COM
,	O
Munich	O
,	O
Germany	O
)	O
,	O
D-dimer	O
was	O
analyzed	O
with	O
the	O
TECHNOZYM	B-BRAND
®	I-BRAND
D-dimer	I-BRAND
ELISA	I-BRAND
(	O
Technoclone	B-COM
,	O
Vienna	O
,	O
Austria	O
)	O
and	O
P-selectin	O
was	O
determined	O
using	O
the	O
Human	B-BRAND
sP-selectin	I-BRAND
Platinum	I-BRAND
ELISA	I-BRAND
(	O
eBioscience	B-COM
,	O
CA	O
)	O
.	O

After	O
incubation	O
,	O
bacteria	O
were	O
removed	O
by	O
washing	O
twice	O
and	O
finally	O
resuspending	O
cells	O
in	O
600	O
ml	O
of	O
respiratory	O
media	O
(	O
RPMI	O
1640	O
without	O
HEPES	O
or	O
NaCO	O
3	O
,	O
pyruvate	O
(	O
2	O
mM	O
)	O
,	O
L-glutamine	O
(	O
2	O
mM	O
)	O
,	O
pH	O
7.5	O
)	O
,	O
containing	O
10	O
%	O
cefotaxime	O
(	O
100	O
mg/ml	O
)	O
(	O
ACS	B-COM
Dobfar	I-COM
Generics	I-COM
S.A.	I-COM
,	O
Luxembourg	O
,	O
Belgium	O
)	O
.	O

Cells	O
were	O
incubated	O
in	O
a	O
CO	O
2	O
free	O
incubator	O
at	O
37	O
8C	O
for	O
1	O
h	O
to	O
allow	O
temperature	O
and	O
pH	O
equilibration	O
,	O
where	O
after	O
the	O
microplate	O
with	O
cells	O
was	O
loaded	O
into	O
the	O
XF24	O
and	O
the	O
oxygen	O
consumption	O
rate	O
of	O
each	O
well	O
was	O
measured	O
over	O
a	O
period	O
of	O
100	O
min	O
.	O

Primers	O
were	O
custom	O
designed	O
and	O
synthesized	O
,	O
taking	O
basic	O
secondary	O
structure	O
into	O
account	O
during	O
the	O
design	O
process	O
(	O
PrimerDesign	B-COM
Ltd.	I-COM
,	O
UK	O
)	O
.	O

All	O
primers	O
were	O
validated	O
against	O
a	O
standard	O
complementary	O
DNA	O
(	O
cDNA	O
)	O
biobank	O
(	O
PrimerDesign	O
)	O
to	O
ensure	O
adequate	O
amplification	O
and	O
single	O
melt-curve	O
products	O
.	O

Albumin	O
was	O
measured	O
in	O
urine	O
using	O
a	O
commercially	O
available	O
immunoturbidimetric	O
assay	O
containing	O
antibody	O
specific	O
for	O
human	O
albumin	O
(	O
Randox	B-COM
Laboratories	I-COM
Ltd	I-COM
,	O
Crumlin	O
,	O
UK	O
)	O
.	O

Creatinine	O
was	O
measured	O
using	O
a	O
modified	O
Jaffe	O
method	O
as	O
previously	O
described	O
(	O
Roche	B-COM
Diagnostics	I-COM
,	O
Indianapolis	O
,	O
IN	O
)	O
(	O
22	O
)	O
.	O

The	O
simulator	O
used	O
was	O
the	O
commercially	O
available	O
Guildford	B-BRAND
MATTU	I-BRAND
TEP	I-BRAND
task	I-BRAND
trainer	I-BRAND
(	O
Limbs	B-COM
&	I-COM
Things	I-COM
,	I-COM
Ltd.	I-COM
,	O
Bristol	O
,	O
UK	O
)	O
,	O
12	O
which	O
consists	O
of	O
an	O
inanimate	O
,	O
box-trainer	O
type	O
simulator	O
replicating	O
the	O
preperitoneal	O
anatomy	O
of	O
a	O
right	O
groin	O
.	O

In	O
2007	O
,	O
the	O
Proximal	B-DEV
Femoral	I-DEV
Locking	I-DEV
Compression	I-DEV
Plate	I-DEV
(	O
PFLCP	B-BRAND
4.5	I-BRAND
/	I-BRAND
5.0	I-BRAND
;	O
Synthes	B-COM
GmbH	I-COM
,	O
Zuchwil	O
,	O
Switzerland	O
)	O
was	O
introduced	O
as	O
a	O
precontoured	O
stainless-steel	B-DEV
plate	I-DEV
,	O
available	O
for	O
left	O
and	O
right	O
femurs	O
,	O
with	O
a	O
fix	O
angled	O
locking	O
interface	O
for	O
the	O
3	O
proximal	B-DEV
screws	I-DEV
(	O
958	O
,	O
1208	O
and	O
1358	O
)	O
and	O
combi-holes	O
in	O
the	O
distal	O
part	O
.	O

GSA	O
in	O
different	O
dosages	O
(	O
37.5	O
nmol	O
;	O
75	O
nmol	O
or	O
150	O
nmol/0	O
.5	O
AL	O
)	O
or	O
phosphate	O
buffered	O
saline	O
(	O
PBS	O
)	O
was	O
injected	O
i.h.	O
with	O
a	O
Microsyringe	B-BRAND
injection	I-BRAND
needle	I-BRAND
(	O
Innovative	B-COM
Labor	I-COM
Systems	I-COM
GmbH	I-COM
,	O
Stqtzerbach	O
,	O
Germany	O
)	O
.	O

The	O
first	O
day	O
mice	O
were	O
i.h.	O
injected	O
unilaterally	O
(	O
left	O
)	O
and	O
the	O
next	O
day	O
in	O
the	O
contralateral	O
(	O
right	O
)	O
hippocampus	O
.	O

Subsequently	O
,	O
the	O
plant	O
material	O
was	O
homogenized	O
to	O
powder	O
using	O
cutting	B-DEV
mill	I-DEV
Pulverisette	B-BRAND
19	I-BRAND
(	O
Fritsch	B-COM
,	O
GmbH	O
,	O
Idar-Oberstein	O
,	O
Germany	O
)	O
and	O
stored	O
in	O
plastic	O
bags	O
prior	O
to	O
the	O
analyses	O
.	O

Serological	O
typing	O
of	O
HLA-B	O
was	O
performed	O
using	O
the	O
standard	O
microlymphocytotoxicity	O
method	O
(	O
Innotrain	B-COM
Diagnostik	I-COM
GmbH	I-COM
,	O
Kronberg	O
,	O
Germany	O
)	O
.	O

HLA-DQB1	O
and	O
HLA-DRB1	O
alleles	O
were	O
detected	O
by	O
HLA-DBR1	O
and	O
HLA-DQB1	O
kits	O
(	O
Olerup	B-BRAND
SSP	I-BRAND
TM	I-BRAND
DQ	I-BRAND
kit	I-BRAND
,	O
Olerup	B-COM
SSP	I-COM
AB	I-COM
,	O
Saltsjöbaden	O
,	O
Sweden	O
)	O
using	O
sequence	O
specific	O
primer	O
(	O
SSP	O
-	O
)	O
PCR	O
method	O
.	O

Materials	O
and	O
methods	O
Materials	O
Cannabidiol	O
(	O
CBD	O
)	O
(	O
purity	O
99.4	O
%	O
)	O
was	O
purchased	O
from	O
THC	B-COM
Pharm	I-COM
GmbH	I-COM
(	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

CBD	O
is	O
practically	O
insoluble	O
in	O
water	O
(	O
0.1	O
mg/mL	O
)	O
but	O
soluble	O
in	O
organic	B-DEV
solvents	I-DEV
such	O
as	O
ethanol	O
,	O
DMSO	O
,	O
and	O
dimethylformamide	O
(	O
certificate	O
of	O
analysis	O
)	O
.	O

At	O
50	O
pmol/cup	O
reactivity	O
of	O
the	O
polyclonal	O
phage	O
was	O
observed	O
selectively	O
for	O
PMP-BSA	O
but	O
not	O
for	O
BSA	O
.	O

BstO	O
I	O
(	O
Promega	B-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
restriction	O
digest	O
of	O
20	O
colony	O
PCR	B-COM
products	O
indicated	O
the	O
presence	O
of	O
seven	O
different	O
clones	O
(	O
4	O
type	O
A	O
,	O
10	O
B	O
,	O
2	O
C	O
,	O
and	O
1	O
D-G	O
)	O
.	O

Insta-Gel	B-BRAND
XF	I-BRAND
and	O
Ultima-Flo	B-BRAND
M	I-BRAND
were	O
purchased	O
from	O
Packard	B-COM
Instrument	I-COM
B.V.	I-COM
(	O
Groningen	O
,	O
Netherlands	O
)	O
.	O

TxB2	O
,	O
12-HETE	O
and	O
12-HHT	O
were	O
purchased	O
from	O
Cayman	B-COM
Chemical	I-COM
Co.	I-COM
.	I-COM

ToF-SIMS	O
analysis	O
Ion	O
images	O
and	O
spectra	O
measurements	O
were	O
performed	O
using	O
a	O
ToFSIMS	B-BRAND
V	I-BRAND
instrument	O
(	O
ION-TOF	B-COM
GmbH	I-COM
,	O
Münster	O
,	O
Germany	O
)	O
with	O
a	O
30	O
keV	O
nano-bismuth	O
primary	O
ion	O
beam	O
source	O
(	O
Bi	O
x	O
y	O
+	O
-	O
cluster	O
ion	O
source	O
with	O
a	O
BiMn	B-DEV
emitter	I-DEV
of	O
the	O
latest	O
generation	O
;	O
lateral	O
resolution	O
in	O
imaging	O
mode	O
70	O
nm	O
,	O
depth	O
resolution	O
9	O
nm	O
)	O
.	O

Chemical	O
used	O
in	O
the	O
study	O
included	O
the	O
competitive	O
antagonist	O
of	O
the	O
NMDA	O
receptors	O
3	O
-	O
(	O
(	O
R	O
)	O
-2-Carboxypiperazin-4-yl	O
)	O
-	O
propyl-1phosphonic	O
acid	O
(	O
CPP	O
,	O
10	O
μM	O
;	O
Tocris	B-COM
Cookson	I-COM
Ltd	I-COM
,	O
UK	O
)	O
.	O

Recordings	O
and	O
data	O
processing	O
Recordings	O
started	O
approximately	O
two	O
hours	O
after	O
the	O
slices	O
were	O
placed	O
in	O
the	O
recording	O
chamber	O
and	O
continued	O
for	O
at	O
least	O
three	O
hours	O
afterwards	O
.	O

Patches	O
were	O
applied	O
for	O
2D	O
to	O
the	O
upper	O
back	O
,	O
using	O
Finn	B-BRAND
Chambers	I-BRAND
Ò	I-BRAND
(	O
Epitest	B-COM
OY	I-COM
,	O
Helsinki	O
,	O
Finland	O
)	O
and	O
Scanpor	B-BRAND
Ò	I-BRAND
tape	I-BRAND
(	O
Norges	B-COM
plaster	I-COM
A/S	I-COM
,	O
Oslo	O
,	O
Norway	O
)	O
.	O

Materials	O
and	O
methods	O
Materials	O
Three	O
different	O
formulations	O
for	O
inhalation	O
of	O
colistimethate	O
sodium	O
were	O
tested	O
:	O
ColiFin	O
1	O
1MIU/3	O
ml	O
(	O
Batch	O
1751691	O
)	O
and	O
ColiFin	O
1	O
2MIU/4	O
ml	O
(	O
Batch	O
1832597	O
)	O
(	O
PARI	B-COM
Pharma	I-COM
GmbH	I-COM
,	O
Starnberg	O
,	O
DE	O
)	O
and	O
Promixin	O
1	O
1MIU/1	O
ml	O
(	O
Batch	O
3K08PM-IT	O
)	O
(	O
Profile	B-COM
Pharma	I-COM
Ltd	I-COM
,	O
Chichester	O
,	O
UK	O
)	O
.	O

1MIU	O
corresponds	O
to	O
80	O
mg	O
of	O
CSM	O
.	O

Physiologic	O
saline	O
solution	O
(	O
sodium	O
chloride	O
0.9	O
%	O
w/v	O
)	O
was	O
obtained	O
by	O
Eurospital	B-COM
Spa	I-COM
(	O
Trieste	O
,	O
IT	O
)	O
;	O
purified	O
water	O
was	O
produced	O
by	O
reverse	O
osmosis	O
(	O
Milli-Q	B-BRAND
Gradient	I-BRAND
system	I-BRAND
,	O
Millipore	B-COM
,	O
Molsheim	O
,	O
FR	O
)	O
.	O

Materials	O
and	O
methods	O
chemicals	O
and	O
consumables	O
Dichloromethane	O
(	O
DcM	O
;	O
>	O
99	O
%	O
)	O
,	O
acetonitrile	O
(	O
Mecn	O
;	O
>	O
99	O
%	O
)	O
,	O
isooctane	O
(	O
>	O
99	O
%	O
)	O
,	O
and	O
aqueous	O
hydrochloric	O
acid	O
≥	O
98.5	O
%	O
;	O
sum	O
of	O
enantiomers	O
]-	O
,	O
Dess-Martin	O
periodinane	O
[	O
1,1,1-tris	O
(	O
acetyloxy	O
)	O
-1,1-dihydro-1,2-benziodoxol-3	O
-	O
(	O
1H	O
)	O
-	O
one	O
,	O
97	O
%	O
]-	O
,	O
and	O
D	O
(	O
+	O
)	O
-	O
glucose	O
(	O
glucose	O
;	O
≥	O
99.5	O
%	O
)	O
were	O
purchased	O
from	O
sigma-Aldrich	B-COM
(	O
steinheim	O
,	O
Germany	O
)	O
.	O

β-Glucuronidase/arylsulfatase	O
from	O
Helix	O
pomatia	O
was	O
supplied	O
by	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
(	O
Mannheim	O
,	O
Germany	O
)	O
.	O

Modified	O
diatomaceous	O
earth	O
solid-supported	O
liquid-liquid	O
extraction	O
(	O
sslle	O
)	O
sorbent	O
material	O
(	O
Isolute	O
HM-n	O
,	O
bulk	O
material	O
)	O
was	O
obtained	O
from	O
biotage	B-COM
Ab	I-COM
(	O
Uppsala	O
,	O
sweden	O
)	O
.	O

empty	O
hard	O
gelatin	B-DEV
capsules	I-DEV
(	O
size	O
0	O
,	O
Ph.eur	O
.	O

quality	O
)	O
were	O
obtained	O
from	O
the	O
University	O
Hospital	O
Pharmacy	O
of	O
erlangen-nuremberg	O
.	O

After	O
critical	O
point	O
drying	O
,	O
the	O
protoplasts	O
were	O
mounted	O
over	O
the	O
stubs	O
with	O
double-sided	O
conductivity	O
tape	O
,	O
and	O
a	O
thin	O
layer	O
of	O
gold	O
metal	O
was	O
applied	O
over	O
the	O
samples	O
using	O
an	O
automated	O
sputter	B-DEV
coater	I-DEV
(	O
K500X	B-BRAND
,	O
Quorum	B-COM
Technologies	I-COM
Ltd	I-COM
,	O
United	O
Kingdom	O
)	O
.	O

The	O
samples	O
were	O
examined	O
under	O
the	O
condition	O
of	O
low	O
vacuum	O
with	O
a	O
secondary	O
electron	O
detector	O
at	O
15	O
kV	O
using	O
SEM	O
(	O
JSM-5600LV	B-BRAND
,	O
JEOL	B-COM
,	O
Japan	O
)	O
at	O
various	O
magnifications	O
(	O
Wang	O
et	O
al.	O
,	O
2010a	O
)	O
.	O

Specified	O
pathogen-free	O
female	O
BALB/c	O
mice	O
(	O
5-6	O
weeks	O
old	O
)	O
were	O
obtained	O
from	O
Harlan	O
Netherlands	O
BV	O
(	O
Horst	O
,	O
The	O
Netherlands	O
)	O
.	O

Mice	O
were	O
housed	O
in	O
Macrolon	O
III	O
cages	O
with	O
food	O
and	O
water	O
ad	O
libitum	O
.	O

The	O
stirring	O
device	O
is	O
a	O
15	O
position	O
submersible	O
magnetic	O
stirrer	O
(	B-BRAND
Variomag	O
HP	O
15	O
,	O
art	O
no	O
41500	O
from	O
H+P	O
Labortechnique	O
Gmbh	O
,	O
Munich	O
Germany	O
)	O
controlled	O
by	O
Variomag	O
Telemodul	O
40	O
S	O
(	B-COM
H+P	O
Labortechnique	O
GmbH	O
,	O
Munich	O
,	O
Germany	O
)	O
.	O

Reverse	O
transcriptase	O
PCR	O
analysis	O
of	O
mRNA	O
levels	O
Total	O
RNA	O
was	O
extracted	O
from	O
normoxic	O
control	O
and	O
48	O
h	O
CH	O
SH-SH5Y	O
cells	O
grown	O
in	O
6-well	O
plates	O
using	O
the	O
RNABee	O
reagent	O
(	B-COM
Biogenesis	O
Ltd.	O
,	O
Poole	O
,	O
UK	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

After	O
removal	O
of	O
the	O
solvent	O
in	O
vacuo	O
,	O
the	O
catalyst	O
precursor	O
was	O
calcined	O
for	O
2	O
h	O
at	O
300	O
8C	O
in	O
a	O
muffle	O
furnace	O
(	B-BRAND
mls	O
1200	O
pyro	O
;	O
MLS	O
GmbH	O
,	O
Leutkirch	O
,	O
Germany	O
)	O
,	O
to	O
afford	O
a	O
catalyst	O
with	O
a	O
loading	O
of	O
1	O
wt	O
%	O
Pd	O
.	O

Total	O
RNA	O
was	O
extracted	O
with	O
RNeasy	O
Mini	O
kit	O
(	B-COM
Qiagen	O
GmbH	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
.	O

cDNA	O
synthesis	O
was	O
performed	O
with	O
500	O
ng	O
RNA	O
using	O
First-Strand	O
cDNA	O
Synthesis	O
Supermix	O
(	B-COM
TransGen	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

The	O
amplifications	O
of	O
the	O
samples	O
were	O
carried	O
out	O
in	O
a	O
final	O
volume	O
of	O
20	O
l	O
using	O
QuantiTect	O
Probe	O
RT-PCR	O
kit	O
(	B-COM
Qiagen	O
GmbH	O
,	O
Hilden	O
,	O
Germany	O
)	O
according	O
to	O
manufacturer	O
's	O
specifications	O
with	O
primers	O
from	O
Generi	O
Biotech	O
(	O
Hradec	O
Králové	O
,	O
Czech	O
Republic	O
)	O
and	O
specific	O
TaqMan	O
probes	O
from	O
the	O
Universal	O
Probe	O
Library	O
(	B-COM
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
that	O
are	O
listed	O
in	O
Table	O
1	O
.	O

The	O
amplifications	O
were	O
run	O
on	O
the	O
LightCycler	O
(	B-COM
Roche	O
Diagnostics	O
GmbH	O
,	O
Mannheim	O
,	O
Germany	O
)	O
according	O
the	O
following	O
program	O
:	O
reverse	O
transcription	O
at	O
50	O
•	O
C	O
for	O
20	O
min	O
and	O
initial	O
activation	O
step	O
at	O
95	O
•	O
C	O
for	O
15	O
min	O
,	O
followed	O
by	O
40	O
cycles	O
at	O
95	O
•	O
C	O
for	O
0	O
s	O
and	O
60	O
•	O
C	O
for	O
60	O
s.	O
Batch	O
and	O
fed-batch	O
cultures	O
were	O
carried	O
out	O
in	O
2-l	O
round-bottomed	O
bioreactors	O
(	B-COM
Electrolab	O
Ltd.	O
,	O
Cytotechnology	O
Tewkesbury	O
,	O
UK	O
)	O
with	O
a	O
starting	O
volume	O
of	O
1	O
l.	O
Exponentially	O
growing	O
cells	O
were	O
inoculated	O
in	O
suspension	O
at	O
2-3	O
9	O
10	O
5	O
cells/ml	O
.	O

Human	O
and	O
rodent	O
neurospheres	O
were	O
cultured	O
in	O
proliferation	O
medium	O
[	O
DMEM	O
and	O
Hams	O
F12	O
(	O
3:1	O
)	O
supplemented	O
with	O
B27	O
(	B-COM
Invitrogen	O
GmBH	O
,	O
Karlsruhe	O
,	O
Germany	O
)	O
,	O
20	O
ng/mL	O
epidermal	O
growth	O
factor	O
(	O
EGF	O
;	O
Biosource	O
,	O
Karlsruhe	O
,	O
Germany	O
)	O
,	O
100	O
U/mL	O
penicillin	O
,	O
and	O
100	O
lg/mL	O
streptomycin	O
]-	O
in	O
a	O
humidified	O
92.5	O
%	O
air/7	O
.5	O
%	O
CO	O
2	O
incubator	O
at	O
37	O
°C	O
in	O
suspension	O
culture	O
.	O

In	O
the	O
present	O
study	O
,	O
all	O
antagonists	O
were	O
ordered	O
commercially	O
(	B-COM
Sigma-Aldrich	O
Chemie	O
Gmbh	O
,	O
Germany	O
)	O
,	O
and	O
were	O
freshly	O
prepared	O
and	O
dissolved	O
in	O
0.9	O
%	O
saline	O
.	O

An	O
adhesive	O
wound	O
paste	O
(	B-BRAND
Solcoseryl	O
Dental	O
Adhesive	O
Paste	O
,	O
MEDA	O
Pharmaceuticals	O
Switzerland	O
GmbH	O
,	O
Wangen-Brüttisellen	O
,	O
Switzerland	O
)	O
was	O
then	O
applied	O
postoperatively	O
,	O
and	O
patients	O
were	O
instructed	O
to	O
apply	O
it	O
twice	O
daily	O
(	O
Fig.	O
1c	O
)	O
.	O

The	O
frequency	O
multiplier	O
AFM6-110	O
,	O
the	O
dual-directional	O
coupler	O
and	O
the	O
three	O
receivers	O
all	O
stem	O
from	O
Radiometer	O
Physics	O
GmbH	O
,	O
Meckenheim	O
,	O
Germany	O
.	O

For	O
the	O
generation	O
of	O
the	O
K	O
u	O
band	O
frequencies	O
two	O
ABSYN420	O
synthesizers	O
(	B-COM
AnaPico	O
,	O
Zurich	O
,	O
Switzerland	O
)	O
were	O
used	O
in	O
steps	O
of	O
250	O
MHz	O
.	O

The	O
applied	O
diagnostic	O
medical	O
device	O
was	O
the	O
non-invasive	O
,	O
Bubble	O
Counter	O
BCC200	O
(	B-COM
GAMPT	O
GmbH	O
,	O
Merseburg	O
,	O
Germany	O
)	O
,	O
a	O
pulsed	O
ultrasonic	O
Doppler	O
system	O
with	O
a	O
transmission	O
frequency	O
of	O
2	O
MHz	O
,	O
measuring	O
microbubbles	O
in	O
the	O
range	O
of	O
10-500	O
µm	O
.	O

HEK293	O
cells	O
were	O
transfected	O
using	O
Genejuice	O
(	B-BRAND
Novagen	O
supplied	O
by	O
Merck	O
Chemicals	O
Ltd	O
,	O
Nottingham	O
,	O
UK	O
;	O
70967-6	O
)	O
as	O
recommended	O
by	O
the	O
manufacturers	O
instructions	O
.	O

All	O
coded	O
transcripts	O
were	O
entered	O
into	O
Atlas.ti	O
5.0.66	O
(	B-COM
Scientific	O
Software	O
Development	O
GmbH	O
,	O
Berlin	O
,	O
Germany	O
)	O
to	O
facilitate	O
review	O
,	O
analysis	O
,	O
and	O
reporting	O
.	O

To	O
a	O
stirring	O
solution	O
of	O
Dy633	O
succinimidyl	O
ester	O
(	O
10	O
mg	O
,	O
0.012	O
mmol	O
)	O
(	B-COM
Dyomics	O
GmbH	O
,	O
Jena	O
,	O
Germany	O
)	O
in	O
1	O
mL	O
anhydrous	O
DMF	O
(	O
stored	O
over	O
molecular	O
sieves	O
)	O
was	O
added	O
18-chloro-3,6,9,12-tetraoxaoctadecan-1-amine	O
hydrochloride	O
as	O
a	O
0.5	O
M	O
solution	O
in	O
DMF	O
(	O
34	O
µL	O
,	O
0.017	O
mmol	O
)	O
followed	O
by	O
diisopropylethylamine	O
(	O
5	O
µL	O
,	O
0.024	O
mmol	O
)	O
.	O

Heart	O
rate	O
,	O
as	O
an	O
indicator	O
for	O
autonomic	O
stress	O
responsiveness	O
,	O
was	O
measured	O
using	O
a	O
portable	O
heart	O
rate	O
monitoring	O
device	O
(	B-BRAND
Polar	O
S810	O
,	O
Polar	O
Electro	O
Oy	O
,	O
Kempele	O
,	O
Finland	O
)	O
,	O
with	O
aggregated	O
beat-to-beat	O
analyses	O
in	O
1-min	O
intervals	O
(	O
beats/min	O
)	O
from	O
À5	O
to	O
+5	O
min	O
relative	O
to	O
the	O
stressor	O
(	O
20	O
units	O
)	O
.	O

Starting	O
on	O
PND	O
123-126	O
,	O
the	O
MS15	O
,	O
MS360	O
and	O
AFR	O
males	O
were	O
placed	O
in	O
adjustable	O
transparent	O
plastic	O
restrainers	O
(	B-COM
AgnTho	B-COM
's	O
AB	O
,	O
Stockholm	O
,	O
Sweden	O
)	O
with	O
a	O
size	O
appropriate	O
to	O
induce	O
immobilization	O
for	O
30	O
min	O
.	O

In	O
vivo	O
chlorophyll	O
a	O
(	O
Chl	O
a	O
)	O
fluorescence	O
of	O
whole	O
plants	O
was	O
recorded	O
using	O
an	O
imaging	O
chlorophyll	O
fluorometer	O
(	B-BRAND
Walz	O
Imaging	O
PAM	O
,	O
Walz	O
GmbH	O
,	O
Effeltrich	O
,	O
Germany	O
)	O
by	O
exposing	O
plants	O
to	O
actinic	O
light	O
(	O
50	O
lmol	O
photons	O
m	O
À2	O
s	O
À1	O
)	O
and	O
after	O
10	O
min	O
a	O
saturating	O
light	O
flash	O
(	O
0.8	O
s	O
,	O
4000	O
lmol	O
photons	O
m	O
À2	O
s	O
À1	O
)	O
to	O
obtain	O
the	O
fluorescence-based	O
effective	O
quantum	O
yield	O
of	O
photosystem	O
II	O
(	O
PSII	O
)	O
in	O
the	O
light	O
(	O
U	O
II	O
)	O
(	O
Genty	O
et	O
al.	O
,	O
1989	O
)	O
.	O

Panorama	O
images	O
were	O
assembled	O
from	O
a	O
series	O
of	O
images	O
and	O
combined	O
by	O
a	O
panoramic	O
stitching	O
software	O
(	B-BRAND
PTGui	O
,	O
New	O
House	O
Internet	O
Services	O
BV	O
,	O
Rotterdam	O
,	O
Netherlands	O
)	O
.	O

For	O
fluorescent	O
imaging	O
,	O
erythrocytes	O
were	O
incubated	O
with	O
300	O
nM	O
nile	O
red	O
(	O
a	O
hydrophobic	O
probe	O
for	O
membrane	O
detection	O
)	O
at	O
room	O
temperature	O
for	O
20	O
min	O
in	O
HBSS	O
.	O

Analysis	O
and	O
data	O
presentation	O
Data	O
were	O
displayed	O
using	O
CHART	O
RUNNER	O
,	O
version	O
3.0	O
(	B-COM
PQ	O
Systems	O
Europe	O
Ltd	O
,	O
Formby	O
,	O
UK	O
)	O
.	O

The	O
standard	O
control	O
chart	O
method	O
was	O
used	O
to	O
interpret	O
patterns	O
of	O
variation	O
in	O
data	O
over	O
time	O
.	O

Adenoid	O
cell	O
separation	O
Adenoids	O
were	O
pressed	O
through	O
a	O
filter	O
in	O
order	O
to	O
eliminate	O
stromal	O
tissue	O
;	O
adenoidal	O
mononuclear	O
cells	O
(	O
AMC	O
)	O
were	O
then	O
isolated	O
by	O
FicollHypaque	O
density	O
gradient	O
centrifugation	O
and	O
re-suspended	O
in	O
complete	O
medium	O
[	O
RPMI	O
1640	O
(	O
Gibco	B-BRAND
,	O
Life	B-COM
Technologies	I-COM
Ltd	I-COM
,	O
Paisley	O
,	O
UK	O
)	O
supplemented	O
with	O
heat-inactivated	O
10	O
%	O
foetal	O
calf	O
serum	O
(	O
FCS	O
;	O
Euroclone	B-COM
)	O
,	O
2.5	O
mmol/l	O
of	O
l-glutamine	O
(	O
Gibco	B-BRAND
)	O
and	O
50	O
lg/ml	O
of	O
gentamycin	O
(	O
Gibco	B-BRAND
)	O
]-	O
.	O

A	O
1.9-cm	O
diameter	O
planar	B-DEV
transducer	I-DEV
(	I-BRAND
model	I-BRAND
V308	I-BRAND
,	O
nominal	O
center	O
frequency	O
=	O
5	O
MHz	O
,	O
Panametrics	B-COM
NDT	I-COM
Ltd.	I-COM
,	O
UK	O
)	O
,	O
was	O
driven	O
by	O
a	O
short	O
duration	O
impulsive	O
signal	O
.	O

Western	O
blot	O
analysis	O
Equal	O
quantity	O
of	O
protein	O
(	O
40	O
g	O
)	O
was	O
electrophoresed	O
on	O
10	O
%	O
SDSpolyacrylamide	O
gel	O
and	O
transferred	O
onto	O
nitrocellulose	O
(	O
Sartorius	B-COM
AG	I-COM
,	O
Germany	O
)	O
Present	O
study	O
R-5	O
-	O
GTGATGGGATTTCCATTGAT-3	O
All	O
the	O
primers	O
were	O
synthesized	O
by	O
Microsynth	B-COM
GmbH	I-COM
,	O
Switzerland	O
.	O

10	O
Forskolin	O
Homo	O
sapiens	O
chromosome	O
10	O
genomic	O
contig	O
reference	O
assembly	O
features	O
in	O
this	O
part	O
of	O
subject	O
sequence	O
:	O
Phospho	O
fructokinase	O
.	O

Semen	O
volume	O
was	O
measured	O
by	O
weighing	O
the	O
collection	O
receptacle	O
with	O
and	O
without	O
semen	O
on	O
a	O
Sartorius	B-BRAND
balance	I-BRAND
(	O
Tillquist	B-COM
Analysis	I-COM
AB	I-COM
,	O
Stockholm	O
,	O
Sweden	O
)	O
.	O

For	O
each	O
specimen	O
,	O
450	O
mL	O
of	O
the	O
ejaculate	O
remaining	O
after	O
the	O
analyses	O
already	O
described	O
in	O
this	O
paragraph	O
was	O
removed	O
with	O
an	O
ordinary	O
airdisplacement	B-DEV
pipette	I-DEV
and	O
then	O
mixed	O
with	O
50	O
mL	O
of	O
benzamidine	O
(	O
0.1	O
M	O
)	O
to	O
stop	O
the	O
biochemical	O
processes	O
involved	O
in	O
liquefaction	O
.	O

SiLi	B-DEV
ZYP	I-DEV
yttrium	I-DEV
oxide	I-DEV
stabilized	I-DEV
zirconia	I-DEV
milling	I-DEV
beads	I-DEV
with	O
0.1-0.2	O
mm	O
diameter	O
were	O
obtained	O
from	O
Sigmund	B-COM
Lindner	I-COM
GmbH	I-COM
(	O
Warmensteinach	O
,	O
Germany	O
)	O
.	O

Water	O
was	O
used	O
in	O
MilliQ	O
grade	O
.	O

Nanosuspension	O
preparation	O
Fenofibrate	O
nanosuspension	O
preparation	O
was	O
performed	O
by	O
wet-milling	O
in	O
a	O
stirred	O
ball	B-DEV
mill	I-DEV
(	O
DynoMill	B-BRAND
RL	I-BRAND
,	O
Willy	O
A.	O
Qualitative	O
data	O
were	O
analyzed	O
using	O
ATLAS.ti	B-BRAND
version	O
7.0	O
(	O
ATLAS.ti	B-COM
GmbH	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

A	O
coding	O
scheme	O
was	O
developed	O
based	O
on	O
the	O
semistructured	O
Cognitive	O
Debriefing	O
Interview	O
Guide	O
and	O
applied	O
to	O
all	O
transcripts	O
.	O

Having	O
been	O
blocked	O
in	O
a	O
blocking	O
buffer-TBS	O
,	O
pH	O
7.5	O
,	O
containing	O
100	O
mM	O
Tris-HCl	O
,	O
0.9	O
%	O
NaCl	O
,	O
0.05	O
%	O
Tween-20	O
[	O
TBS-T	O
]-	O
,	O
and	O
1	O
%	O
bovine	O
serum	O
albumin	O
,	O
sections	O
were	O
incubated	O
with	O
primary	O
rabbit	O
polyclonal	O
antibodies	O
against	O
hCG	O
(	O
DAKO	B-COM
A/S	I-COM
,	O
Glostrup	O
,	O
Denmark	O
)	O
and	O
sheep	O
polyclonal	O
antibodies	O
against	O
LH/hCGR	O
(	O
Biotrend	B-COM
Chemikalien	I-COM
GmbH	I-COM
,	O
Cologne	O
,	O
Germany	O
)	O
,	O
both	O
diluted	O
1:200	O
in	O
the	O
same	O
solution	O
for	O
60	O
min	O
at	O
37	O
°C	O
in	O
a	O
humidified	B-DEV
chamber	I-DEV
and	O
washed	O
for	O
60	O
min	O
in	O
TBS-T	O
.	O

Spirometry	O
:	O
FEV	O
1	O
was	O
measured	O
by	O
spirometer	B-DEV
(	O
Master	B-BRAND
Screen	I-BRAND
,	O
Erich	B-COM
Jaeger	I-COM
GmbH	I-COM
,	O
Wuerzburg	O
,	O
Germany	O
)	O
;	O
the	O
highest	O
of	O
three	O
successive	O
measurements	O
was	O
taken	O
.	O

Maleic	O
acid	O
(	O
99	O
%	O
pure	O
,	O
lot	O
4039128	O
)	O
was	O
purchased	O
from	O
Sigma-Aldrich	B-COM
Chemie	I-COM
GmbH	I-COM
(	O
Steinheim	O
,	O
Germany	O
)	O
.	O

Sodium	O
oleate	O
(	O
82.7	O
%	O
pure	O
,	O
lot	O
51110	O
)	O
was	O
obtained	O
from	O
Riedel-de	B-COM
Haën	I-COM
,	O
Seelze	O
,	O
Germany	O
.	O

The	O
integral	O
data	O
were	O
grouped	O
and	O
sorted	O
,	O
and	O
then	O
the	O
spectral	O
intensity	O
was	O
normalized	O
to	O
a	O
unit	O
area	O
with	O
the	O
appropriate	O
weighting	O
coefficients	O
in	O
Microsoft	O
®	O
Excel	O
spreadsheets	O
prior	O
to	O
importing	O
into	O
the	O
SIMCA-P	B-BRAND
v11	O
.0	O
software	B-DEV
package	I-DEV
(	O
Umetrics	B-COM
AB	I-COM
,	O
Umeå	O
,	O
Sweden	O
)	O
for	O
multivariate	O
data	O
analysis	O
.	O

PCA	O
was	O
conducted	O
for	O
the	O
entire	O
dataset	O
using	O
mean-centered	O
data	O
.	O

The	O
reaction	O
was	O
carried	O
out	O
in	O
50	O
ml	O
volumes	O
containing	O
0.3	O
mg/ml	O
BSA	O
(	O
Bovine	O
Serum	O
Albumin	O
)	O
,	O
250	O
mM	O
dTNPs	O
,	O
0.5	O
mM	O
of	O
each	O
primer	O
,	O
0.02	O
U	O
Phusion	B-BRAND
High-Fidelity	I-BRAND
DNA	I-BRAND
Polymerase	I-BRAND
(	O
Finnzymes	B-COM
OY	I-COM
,	O
Espoo	O
,	O
Finland	O
)	O
and	O
5x	O
Phusion	B-BRAND
HF	I-BRAND
Buffer	I-BRAND
containing	O
1.5	O
mM	O
MgCl	O
2	O
.	O

Expired	O
13	O
CO	O
2	O
enrichment	O
was	O
measured	O
using	O
a	O
continuous	O
flow	O
isotope	B-DEV
ratio	I-DEV
mass	I-DEV
spectrometer	I-DEV
(	O
IRMS	O
,	O
Isoprime	B-COM
Ltd	I-COM
,	O
Cheadle	O
,	O
UK	O
)	O
and	O
expressed	O
as	O
atom	O
percent	O
excess	O
(	O
APE	O
)	O
when	O
compared	O
against	O
a	O
reference	O
standard	O
of	O
compressed	O
CO	O
2	O
.	O

a	O
Healthy	O
children	O
were	O
selected	O
to	O
represent	O
the	O
wide	O
range	O
in	O
age	O
of	O
PKU	O
children	O
recruited	O
for	O
the	O
study	O
(	O
see	O
Table	O
2	O
)	O
.	O

Previous	O
studies	O
(	O
e.g.	O
17	O
)	O
have	O
shown	O
when	O
such	O
feedback	O
is	O
used	O
,	O
there	O
are	O
no	O
significant	O
changes	O
in	O
the	O
levels	O
of	O
activity	O
maintained	O
by	O
the	O
*	O
Digitimer	B-COM
Ltd	I-COM
,	O
Hertfordshire	O
,	O
UK	O
.	O

†	O
Gould	B-COM
Electronics	I-COM
Inc.	I-COM
,	O
Chandler	O
,	O
AZ	O
,	O
USA	O
.	O

subjects	O
from	O
one	O
sequence	O
to	O
another	O
.	O

Immunodepletion	O
of	O
DNA	O
helicase	O
and	O
ssDNA-dependent	O
ATPase	O
activities	O
of	O
PfH45	B-DEV
Aliquots	O
of	O
30	O
nM	O
purified	O
PfH45	O
were	O
incubated	O
separately	O
at	O
4	O
°C	O
for	O
16	O
h	O
with	O
2	O
μg	O
of	O
PfH45	O
IgG	O
,	O
preimmune	O
IgG	O
or	O
penta-His	O
antibodies	O
(	O
Qiagen	B-COM
,	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

Immunodepletion	O
was	O
performed	O
by	O
adding	O
10	O
μl	O
of	O
protein	O
A-Sepharose	O
beads	O
(	O
Amersham	B-COM
)	O
equilibrated	O
in	O
100	O
mM	O
Tris-HCl	O
buffer	O
(	O
pH	O
8.0	O
)	O
.	O

The	O
applied	O
voltage	O
was	O
monitored	O
using	O
an	O
oscilloscope	B-DEV
(	O
TDS	B-BRAND
210	I-BRAND
,	O
Tektronix	B-COM
,	B-COM
UK	I-COM
Ltd.	I-COM
,	O
Bracknell	O
,	O
UK	O
)	O
.	O

Microscopy	O
pictures	O
and	O
videos	O
were	O
generated	O
using	O
a	O
Dino-Lite	O
digital	B-DEV
microscope	I-DEV
(	O
AM413T5	B-BRAND
Dino-Lite	I-BRAND
Pro	I-BRAND
,	O
AnMo	B-COM
Electronics	I-COM
Corporation	I-COM
,	O
Hsinchu	O
,	O
Taiwan	O
)	O
.	O

Twin-beam	O
DE-CTA	O
was	O
performed	O
using	O
a	O
128-slice	O
singlesource	O
CT	B-DEV
scanner	I-DEV
(	O
CT	B-BRAND
Definition	I-BRAND
AS	I-BRAND
+	I-BRAND
;	O
Siemens	B-COM
Healthcare	I-COM
GmbH	I-COM
,	O
Erlangen	O
,	O
Germany	O
)	O
equipped	O
with	O
a	O
split-filter	B-DEV
and	O
a	O
single-layer	O
integrated	B-DEV
circuit	I-DEV
detector	I-DEV
(	O
Stellar	B-BRAND
;	O
Siemens	B-COM
Healthcare	I-COM
,	O
Forchheim	O
,	O
Germany	O
)	O
.	O

PCR	O
was	O
performed	O
with	O
specific	O
primers	O
using	O
200	O
ng	O
of	O
the	O
bisulfite-modified	O
genomic	O
DNA	O
as	O
templates	O
and	O
EpiTect	B-BRAND
MSP	I-BRAND
kit	I-BRAND
(	O
QIAGEN	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

The	O
cycling	O
conditions	O
consisted	O
of	O
an	O
initial	O
denaturation	O
step	O
at	O
95	O
°C	O
for	O
5	O
min	O
,	O
followed	O
by	O
31	O
cycles	O
at	O
94	O
°C	O
for	O
30	O
s	O
,	O
55	O
°C	O
for	O
30	O
s	O
,	O
and	O
72	O
°C	O
for	O
45	O
s	O
,	O
the	O
PCR	O
products	O
(	O
15	O
μl	O
)	O
were	O
resolved	O
on	O
a	O
3	O
%	O
agarose	O
gel	O
.	O

Gene	O
Ontology	O
Analysis	O
Gene	O
Ontology	O
(	O
GO	O
)	O
analysis	O
was	O
performed	O
using	O
GOSSIP	B-BRAND
27	I-BRAND
-	O
a	O
freely	O
available	O
software	B-DEV
package	I-DEV
that	O
tests	O
whether	O
a	O
molecular	O
function	O
,	O
biological	O
process	O
or	O
cellular	O
location	O
described	O
in	O
the	O
GO	O
system	O
(	O
http://www.geneontology.org/	O
)	O
,	O
the	O
so-called	O
GO	O
terms	O
,	O
is	O
significantly	O
associated	O
with	O
a	O
group	O
of	O
interesting	O
genes	O
when	O
compared	O
with	O
a	O
reference	O
group	O
(	O
MicroDiscovery	B-COM
GmbH	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

cDNA	O
Synthesis	O
,	O
Quantitative	O
Real-Time	O
PCR	O
and	O
Statistical	O
Analysis	O
cDNA	O
was	O
obtained	O
by	O
oligo	O
(	O
dT	O
)	O
16	O
-	O
primed	O
reverse	O
transcription	O
of	O
1	O
mg	O
total	O
RNA	O
using	O
SuperScript	B-BRAND
II	I-BRAND
(	O
Invitrogen	B-COM
)	O
.	O

Chemicals	O
Erdosteine	O
(	O
Erdostin	O
suspension	O
)	O
was	O
obtained	O
from	O
Ilsan-iltas	B-COM
Pharmaceuticals	I-COM
(	O
Istanbul	O
,	O
Turkey	O
)	O
,	O
and	O
ALA	O
was	O
obtained	O
from	O
Sigma-Aldrich	B-COM
Chemie	I-COM
GmbH	I-COM
(	O
Steinheim	O
,	O
Germany	O
)	O
.	O

Ketamine	O
hydrochloride	O
(	O
Ketalar	B-BRAND
50	O
mg/ml	O
)	O
was	O
obtained	O
from	O
Pfizer	B-COM
(	O
Turkey	O
)	O
,	O
and	O
xylasine	O
hydrochloride	O
(	O
Rompun	B-BRAND
)	O
was	O
obtained	O
from	O
Bayer	B-COM
(	O
Turkey	O
)	O
.	O

Entrapment	O
efficiency	O
and	O
drug	O
loading	O
capacity	O
Entrapment	O
efficiency	O
(	O
EE	O
%	O
)	O
and	O
drug	O
loading	O
capacity	O
(	O
DL	O
%	O
)	O
of	O
T-NPs	O
were	O
calculated	O
as	O
previously	O
described	O
2	O
DL	O
%	O
(	O
PTX	O
)	O
=	O
content	O
of	O
PTX	O
entrapped	O
in	O
nanoparticles	O
weight	O
of	O
nanoparticles	O
×	O
100	O
Particle	O
size	O
and	O
zeta	O
potential	O
The	O
mean	O
diameter	O
and	O
zeta-potential	O
of	O
T-NPs	O
were	O
measured	O
at	O
25	O
o	O
C	O
by	O
a	O
8	O
Zetasizer	B-BRAND
Nano	I-BRAND
ZS	I-BRAND
(	O
Malvern	B-COM
Instruments	I-COM
,	I-COM
Ltd.	I-COM
,	O
Malvern	O
,	O
Worcestershire	O
,	O
UK	O
)	O
.	O

All	O
the	O
tests	O
were	O
run	O
3	O
times	O
and	O
all	O
data	O
were	O
expressed	O
as	O
the	O
mean	O
±	O
SD	O
.	O

Serum	O
LH	O
,	O
FSH	O
,	O
and	O
testosterone	O
concentrations	O
were	O
measured	O
by	O
chemiluminescent	O
assay	O
using	O
an	O
ACS	B-BRAND
:	B-BRAND
180	B-BRAND
autoanalyzer	B-DEV
(	O
Bayer	B-COM
Corp.	I-COM
.	I-COM

Diagnostics	I-COM
GmbH	I-COM
,	O
Leverkusen	O
,	O
Germany	O
)	O
.	O

The	O
concentrations	O
of	O
DHEA	O
,	O
dehydroepiandrosterone-sulfate	O
(	O
DHEAS	O
)	O
and	O
androstenedione	O
were	O
determined	O
by	O
RIA	O
methods	O
(	O
Immunotech	B-COM
,	O
Marseille	O
,	O
France	O
)	O
.	O

The	O
vendor-provided	O
software	B-DEV
CST	B-BRAND
Microwave	I-BRAND
Studio	I-BRAND
(	O
CST	B-BRAND
MICROWAVE	I-BRAND
STUDIO	I-BRAND
,	O
CST	B-COM
GmbH	I-COM
,	O
Darmstadt	O
,	O
Germany	O
)	O
was	O
used	O
to	O
compute	O
the	O
electromagnetic	O
fields	O
.	O

The	O
signals	O
are	O
amplified	O
and	O
converted	O
into	O
NIM	O
(	O
nuclear	O
instrumentation	O
module	O
)	O
standard	O
pulses	O
using	O
an	O
ATR19-8	B-BRAND
amplifier/constant	B-DEV
fraction	I-DEV
discriminator	I-DEV
(	O
CFD	O
)	O
(	O
Roentdek	B-COM
GmbH	I-COM
,	O
Frankfurt	O
,	O
Germany	O
)	O
.	O

A	O
TDC8HP	B-BRAND
time-to-digital	B-DEV
converter	I-DEV
(	O
TDC	B-DEV
)	O
PCI	B-DEV
card	I-DEV
(	O
Roentdek	B-COM
GmbH	I-COM
,	O
Frankfurt	O
,	O
Germany	O
)	O
is	O
used	O
to	O
feed	O
the	O
signal	O
into	O
a	O
computer	O
with	O
a	O
time	O
resolution	O
of	O
25	O
ps	O
.	O

Food	O
was	O
reweighed	O
at	O
1	O
,	O
2	O
,	O
4	O
,	O
6	O
,	O
and	O
24	O
h	O
after	O
injection	O
,	O
whereas	O
body	O
weight	O
and	O
water	O
intake	O
were	O
measured	O
24	O
h	O
after	O
injection	O
using	O
a	O
Fisher	B-BRAND
Scientific	I-BRAND
FP-300	I-BRAND
series	O
balance	B-DEV
(	O
Fisher	B-COM
Scientific	I-COM
Ltd.	I-COM
,	O
Leicester	O
,	O
UK	O
)	O
.	O

On	O
each	O
experimental	O
occasion	O
,	O
the	O
behavior	O
of	O
each	O
hamster	O
was	O
monitored	O
in	O
its	O
home	O
cage	O
for	O
5	O
sec	O
in	O
every	O
minute	O
for	O
1	O
h	O
after	O
lights	O
off	O
,	O
as	O
previously	O
described	O
(	O
13,14,29	O
)	O
.	O

Photosynthesis	O
and	O
respiration	O
versus	O
temperature	O
responses	O
Cells	O
grown	O
at	O
10	O
°C	O
in	O
logarithmic	O
growth	O
phase	O
were	O
collected	O
by	O
centrifugation	O
,	O
resuspended	O
in	O
a	O
fresh	O
BG11	O
medium	O
(	O
supplemented	O
with	O
10	O
mM	O
NaHCO	O
3	O
)	O
and	O
transferred	O
to	O
the	O
Clark	B-BRAND
oxygen	I-BRAND
electrode	I-BRAND
(	O
Hansatech	B-COM
Instruments	I-COM
Ltd.	I-COM
,	O
Norfolk	O
,	O
UK	O
)	O
chamber	O
.	O

Photosynthesis	O
under	O
the	O
saturation	O
intensity	O
(	O
about	O
700	O
lmol	O
photons	O
m	O
-2	O
s	O
-1	O
)	O
and	O
respiration	O
versus	O
temperature	O
responses	O
were	O
measured	O
at	O
5	O
,	O
10	O
,	O
15	O
,	O
20	O
,	O
25	O
,	O
30	O
and	O
35	O
°C	O
,	O
respectively	O
.	O

Methods	O
:	O
Animal	O
Studies	O
Animal	O
Husbandry	O
.	O

C57Bl/6J	B-BRAND
female	O
mice	B-DEV
(	O
Envigo	B-COM
Ltd	I-COM
,	O
United	O
Kingdom	O
)	O
were	O
housed	O
on	O
a	O
12	O
hour	O
lightdark	O
cycle	O
at	O
21-23	O
°C	O
with	O
free	O
access	O
to	O
food	O
(	O
Beekay	O
Rat	O
and	O
Mouse	O
Diet	O
,	O
Bantin	O
&	O
Kingman	O
,	O
Hull	O
,	O
UK	O
)	O
and	O
water	O
.	O

Samples	O
were	O
transferred	O
into	O
two	O
low	O
mass	O
aluminum	B-DEV
planchettes	I-DEV
and	O
high	O
pressure	O
frozen	O
(	O
Engineering	B-COM
Office	I-COM
M.	I-COM
Wohlwend	I-COM
GmbH	I-COM
,	O
Sennwald	O
,	O
Switzerland	O
)	O
to	O
maintain	O
the	O
native	O
structure	O
of	O
the	O
gel	O
.	O

P188	O
Methods	O
We	O
assessed	O
changes	O
in	O
fl	O
uid	O
balance	O
and	O
performed	O
daily	O
BIA	O
(	O
using	O
a	O
Maltron	B-BRAND
BioScan	I-BRAND
920-II	I-BRAND
;	O
Maltron	B-COM
International	I-COM
Ltd	I-COM
,	O
UK	O
)	O
over	O
3	O
days	O
in	O
consecutive	O
ICU	O
admissions	O
with	O
LOS	O
>	O
72	O
hours	O
.	O

Data	O
analysis	O
Data	O
were	O
analyzed	O
using	O
Stats	B-BRAND
Direct	I-BRAND
(	O
Stats	B-COM
Direct	I-COM
Ltd.	I-COM
,	O
Cheshire	O
,	O
UK	O
)	O
.	O

A	O
Chi	O
square	O
analysis	O
with	O
untransformed	O
data	O
was	O
used	O
for	O
sample	O
comparison	O
and	O
differences	O
were	O
considered	O
significant	O
at	O
P	O
<	O
0.01	O
.	O

Reagents	O
Dulbecco	O
's	O
modified	O
Eagle	O
medium	O
(	O
DMEM	O
)	O
,	O
penicillin	O
,	O
streptomycin	O
,	O
L-glutamine	O
,	O
Hank	O
's	O
calcium-and	O
magnesium-free	O
balanced	O
salt	O
solution	O
(	O
HBSS	O
)	O
,	O
and	O
fetal	O
calf	O
serum	O
(	O
FCS	O
)	O
were	O
purchased	O
from	O
GIBCO	B-COM
Life	I-COM
Technologies	I-COM
,	I-COM
Ltd.	I-COM
,	O
UK	O
.	O

Halothane	O
was	O
supplied	O
by	O
May	B-COM
and	I-COM
Baker	I-COM
,	I-COM
Ltd.	I-COM
,	O
Dagenham	O
,	O
UK	O
,	O
and	O
alcoholic	O
Betadine	O
(	O
povidine	O
iodine	O
)	O
was	O
supplied	O
by	O
Napp	B-COM
Laboratories	I-COM
,	I-COM
Ltd.	I-COM
,	O
Cambridge	O
,	O
UK	O
.	O

For	O
sequencing	O
,	O
the	O
3L	O
and	O
4L	O
CEACAM1	O
PCR	O
products	O
were	O
excised	O
from	O
the	O
agarose	O
gel	O
,	O
purified	O
using	O
the	O
QIAquick	B-BRAND
Gel	B-DEV
Extraction	I-DEV
kit	I-DEV
(	O
Qiagen	B-COM
,	B-COM
VWR	I-COM
International	I-COM
AB	I-COM
,	O
Stockholm	O
,	O
Sweden	O
)	O
and	O
quantified	O
using	O
lambda	O
DNA	O
.	O

The	O
amplification	O
was	O
performed	O
in	O
20	O
ml	O
reactions	O
containing	O
BigDye	B-BRAND
mix	I-BRAND
(	O
Applied	B-COM
Biosystems	I-COM
,	O
Warrington	O
,	O
UK	O
)	O
,	O
5-7	O
ml	O
template	O
and	O
3.2	O
mM	O
of	O
the	O
forward	O
CEACAM1	O
primer	O
at	O
551C	O
for	O
26	O
cycles	O
.	O

DNA	O
sequencing	O
For	O
DNA	O
sense	O
and	O
antisense	O
sequencing	O
,	O
PCR	O
products	O
were	O
purified	O
from	O
agarose	O
gels	O
using	O
Quiaex	B-BRAND
II	I-BRAND
gel	B-DEV
extraction	I-DEV
kit	I-DEV
(	O
Quiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Forward	O
and	O
reverse	O
sequencing	O
reactions	O
were	O
performed	O
with	O
the	O
BigDye	B-BRAND
TM	I-BRAND
terminator	B-DEV
cycle	I-DEV
sequencing	I-DEV
ready	I-DEV
reaction	I-DEV
kit	I-DEV
(	O
Applied	B-COM
Biosystems	I-COM
,	O
Warrington	O
,	O
UK	O
)	O
on	O
an	O
ABI	B-BRAND
Prism	I-BRAND
TM	I-BRAND
377	I-BRAND
DNA	B-DEV
sequencer	I-DEV
(	O
Applied	B-COM
Biosystems	I-COM
,	O
Warrington	O
,	O
UK	O
)	O
in	O
all	O
subjects	O
with	O
abnormal	O
DGGE	O
mobility	O
patterns	O
.	O

Thereafter	O
,	O
a	O
slow	O
infusion	O
of	O
1.25	O
μl/ml	O
fentanyl	O
(	O
Fentanyl	B-BRAND
,	O
Pharmalink	B-COM
AB	I-COM
,	O
Stockholm	O
,	O
Sweden	O
)	O
in	O
buffered	O
glucose	O
(	O
25	O
mg/ml	O
)	O
was	O
started	O
at	O
a	O
rate	O
of	O
1.5	O
ml/min	O
and	O
adjusted	O
as	O
needed	O
.	O

The	O
prepared	O
specimens	O
were	O
mounted	O
on	O
aluminum	O
stubs	O
,	O
gold-sputtered	O
at	O
10	O
mA	O
for	O
1	O
min	O
(	O
Unit	B-BRAND
E500	I-BRAND
,	O
Polaron	B-COM
Equipment	I-COM
Ltd.	I-COM
,	O
Watford	O
,	O
UK	O
)	O
and	O
analyzed	O
under	O
SEM	O
(	O
1430	B-BRAND
VP	I-BRAND
,	O
LEO	B-COM
Electron	I-COM
Microscopy	I-COM
Ltd.	I-COM
,	O
Cambridge	O
,	O
UK	O
)	O
.	O

The	O
specimens	O
were	O
cut	O
in	O
half	O
using	O
a	O
diamond	B-DEV
disk	I-DEV
adapted	O
to	O
a	O
precision	O
cutting	B-DEV
machine	I-DEV
(	O
Isomet	B-BRAND
4000	I-BRAND
,	O
Buehler	B-COM
GmbH	I-COM
,	O
40599	O
Dusseldorf	O
,	O
Germany	O
)	O
.	O

The	O
two	O
fragments	O
of	O
each	O
specimen	O
were	O
randomly	O
assigned	O
to	O
the	O
LM	O
and	O
SEM	O
analysis	O
groups	O
.	O

Primers	O
were	O
designed	O
using	O
the	O
program	B-DEV
Primer	B-BRAND
Premier	I-BRAND
(	O
Premier	B-COM
Biosoft	I-COM
,	O
USA	O
)	O
and	O
synthesized	O
using	O
a	O
DNA/RNA	B-DEV
Synthesizer	I-DEV
OligoMaker	B-BRAND
48/6	I-BRAND
(	O
OligoMaker	B-COM
ApS	I-COM
,	O
Denmark	O
)	O
.	O

The	O
sequencing	O
and	O
phylogenetic	O
analysis	O
of	O
these	O
genes	O
were	O
performed	O
as	O
described	O
for	O
the	O
16S	O
rDNA	O
and	O
ITS	O
.	O

The	O
purity	O
of	O
selected	O
fractions	O
was	O
verified	O
by	O
MALDI-TOF	O
(	O
Autoflex	B-BRAND
II	I-BRAND
TOF/TOF	I-BRAND
;	O
Bruker	B-COM
Daltonics	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
,	O
analytical	O
reverse-phase	O
HPLC	O
,	O
and	O
size	O
exclusion	O
chromatography	O
as	O
described	O
previously	O
(	O
11	O
)	O
.	O

The	O
p53	O
wild-type	O
(	O
SKW6	O
.4	O
and	O
JVM-2	O
)	O
and	O
p53	O
mutated	O
(	O
BJAB	O
,	O
MAVER	O
)	O
B	O
leukemic	O
lines	O
were	O
purchased	O
from	O
DSMZ	B-COM
(	O
Deutsche	B-COM
Sammlung	I-COM
von	I-COM
Mikroorganismen	I-COM
und	I-COM
Zellkulturen	I-COM
GmbH	I-COM
,	O
Braunschweig	O
,	O
Germany	O
)	O
.	O

Leukemic	O
cells	O
were	O
routinely	O
cultured	O
in	O
RPMI-1640	O
medium	O
(	O
Gibco	B-COM
BRL	I-COM
,	O
Grand	O
Island	O
,	O
NY	O
)	O
.	O

For	O
secondary	O
PCR	O
amplification	O
of	O
the	O
D3S1581	O
marker	O
,	O
12.5	O
ml	O
of	O
MegaMix-double	B-BRAND
(	O
Microzone	B-COM
Ltd.	I-COM
,	O
Haywards	O
Heath	O
,	O
UK	O
)	O
,	O
and	O
2	O
pmol	O
of	O
each	O
forward	O
and	O
reverse	O
D3S1581	O
primer	O
were	O
used	O
in	O
a	O
25	O
ml	O
reaction	O
.	O

Measurement	O
of	O
hematological	O
traits	O
We	O
measured	O
Hb	O
concentration	O
in	O
whole	O
blood	O
using	O
a	O
HemoCue	B-BRAND
Hb	I-BRAND
201	I-BRAND
+	I-BRAND
analyzer	B-DEV
,	O
following	O
the	O
manufacturer	O
's	O
protocol	O
(	O
HemoCue	B-COM
AB	I-COM
,	O
Ängelholm	O
,	O
Sweden	O
)	O
.	O

We	O
measured	O
Hct	O
as	O
the	O
volume	O
of	O
packed	O
RBCs	O
relative	O
to	O
total	O
blood	O
volume	O
in	O
a	O
heparinized	B-DEV
capillary	I-DEV
tube	I-DEV
that	O
was	O
spun	O
at	O
13,600	O
g	O
for	O
5	O
min	O
in	O
a	O
ZIPocrit	B-BRAND
centrifuge	B-DEV
(	O
LW	B-COM
Scientific	I-COM
Inc.	I-COM
,	O
Lawrenceville	O
,	O
GA	O
,	O
USA	O
)	O
.	O

After	O
a	O
subsequent	O
wash	O
in	O
PBS-T	O
,	O
membranes	B-DEV
were	O
incubated	O
with	O
a	O
streptavidin	O
conjugated	O
Horseradish	O
Peroxidase	O
(	O
Amersham	B-COM
,	O
GE	B-COM
Healthcare	I-COM
UK	I-COM
Ltd.	I-COM
,	O
Little	O
Chalfont	O
,	O
UK	O
)	O
diluted	O
1:3000	O
in	O
PBS-T	O
,	O
for	O
1	O
h	O
at	O
room	O
temperature	O
.	O

Materials	O
and	O
Methods	O
The	O
Endo-Model	B-BRAND
rotating-hinge	B-DEV
knee	I-DEV
prosthesis	I-DEV
was	O
developed	O
in	O
1979	O
by	O
Waldemar	B-COM
LINK	I-COM
GmbH	I-COM
(	O
Hamburg	O
,	O
Germany	O
)	O
.	O

3	O
The	O
stem	O
of	O
the	O
femoral	O
component	O
has	O
a	O
valgus	O
angle	O
of	O
6	O
°	O
.	O

Images	O
were	O
acquired	O
with	O
AxioVision	B-BRAND
(	O
version	O
4.8.3.0	O
;	O
Carl	B-COM
Zeiss	I-COM
MicroImaging	I-COM
GmbH	I-COM
,	O
Jena	O
,	O
Germany	O
)	O
.	O

All	O
neuronal	B-DEV
cell	I-DEV
bodies	I-DEV
in	O
the	O
DRGs	O
were	O
identified	O
as	O
positive	O
for	O
bIII	O
tubulin	O
.	O

Pre-and	O
post-surgery	O
care	O
One	O
hour	O
before	O
operation	O
,	O
buprenorphine	O
(	O
0.05	O
mg/kg	O
;	O
RB	B-COM
Pharmaceuticals	I-COM
Ltd	I-COM
,	O
Berkshire	O
,	O
UK	O
)	O
was	O
administrated	O
subcutaneously	O
(	O
s/c	O
)	O
as	O
analgesic	O
.	O

Patient	O
dosimetry	O
is	O
performed	O
using	O
external	O
KAP-meter	B-BRAND
(	O
RTI	B-COM
Electronics	I-COM
AB	I-COM
,	O
Gothenburg	O
,	O
Sweden	O
)	O
and	O
radiochromic	B-DEV
films	I-DEV
(	O
Gafchromic	B-BRAND
XRRV2	I-BRAND
,	O
International	B-COM
Specialty	I-COM
Products	I-COM
)	O
.	O

Monoclonal	O
antibody	O
against	O
glyceraldehyde-3-phosphate	O
dehydrogenase	O
(	O
GAPDH	O
)	O
was	O
from	O
Serotec	B-COM
Ltd	I-COM
(	O
Oxford	O
,	O
UK	O
)	O
.	O

Polyclonal	O
rabbit	O
antimouse	O
immunoglobulins/HRP	O
was	O
from	O
Dakocytomation	B-COM
(	O
Glostrup	O
,	O
Denmark	O
)	O
.	O

The	O
40	O
kHz	O
ultrasound	B-DEV
apparatus	I-DEV
was	O
a	O
standard	O
ultrasonic	B-DEV
cleaning	I-DEV
bath	I-DEV
375H	I-DEV
(	O
Langford	B-COM
Electronics	I-COM
Ltd.	I-COM
,	O
Coventry	O
,	O
UK	O
)	O
with	O
a	O
maximal	O
electrical	O
energy	O
output	O
of	O
75	O
W	O
.	O

The	O
supernatant	O
was	O
evaporated	O
until	O
dryness	O
(	O
partial	O
vacuum	O
at	O
45	O
°C	O
,	O
SPD2010	B-BRAND
SpeedVac	I-BRAND
System	I-BRAND
,	O
Thermo	B-COM
Fisher	I-COM
Scientific	I-COM
GmbH	I-COM
,	O
Dreieich	O
,	O
Germany	O
)	O
.	O

Residues	O
were	O
resolved	O
in	O
200	O
μL	O
of	O
methanol	O
,	O
77.5	O
mL	O
of	O
nanopure	O
H	O
2	O
O	O
,	O
and	O
22.5	O
μL	O
of	O
HCl	O
(	O
10	O
mol/L	O
)	O
.	O

Recording	O
of	O
the	O
pupil	O
diameter	O
in	O
darkness	O
by	O
near-infrared	O
TV	O
(	O
television	O
)	O
pupillography	O
was	O
performed	O
20	O
minutes	O
after	O
dark	O
adaptation	O
using	O
the	O
compact	O
integrated	B-DEV
pupillograph	I-DEV
(	O
AMTech	B-COM
GmbH	I-COM
,	O
Weinheim	O
)	O
in	O
a	O
standardized	O
way	O
.	O

8	O
Devices	O
for	O
automatic	O
24-hour	O
recording	O
of	O
ambulatory	O
BP	O
(	O
Boso	B-COM
GmbH	I-COM
,	O
Jüngingen	O
,	O
Germany	O
)	O
were	O
used	O
at	O
various	O
measurement	O
intervals	O
(	O
every	O
15	O
minutes	O
during	O
the	O
day	O
and	O
every	O
30	O
minutes	O
at	O
night	O
)	O
.	O


,	O
the	O
GenoType	B-BRAND
MTBDRplus	I-BRAND
assay	I-BRAND
(	O
Hain	B-COM
Lifescience	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
(	O
35	O
)	O
(	O
36	O
)	O
(	O
37	O
)	O
.	O

A	O
notable	O
drawback	O
to	O
these	O
assays	O
is	O
that	O
they	O
are	O
limited	O
to	O
detecting	O
a	O
specific	O
set	O
of	O
mutations	O
in	O
the	O
rpoB	O
,	O
katG	O
,	O
and	O
inhA	O
genes	O
(	O
e.g.	O
,	O
the	O
INNO-LiPA	B-BRAND
Rif.TB	I-BRAND
test	I-BRAND
detects	O
only	O
nine	O
mutations	O
in	O
rpoB	O
)	O
and	O
can	O
not	O
identify	O
novel	O
mutations	O
conferring	O
resistance	O
(	O
37	O
)	O
,	O
although	O
certain	O
assays	O
do	O
contain	O
probes	O
for	O
wildtype	O
alleles-observing	O
a	O
resistance	O
phenotype	O
and	O
a	O
wild-type	O
allele	O
would	O
suggest	O
a	O
novel	O
mutation	O
but	O
would	O
not	O
provide	O
further	O
details	O
.	O

Cultures	O
were	O
synchronized	O
in	O
G1	O
with	O
alpha	O
factor	O
mating	O
pheromone	O
for	O
3	O
h	O
(	O
CASLO	B-COM
ApS	I-COM
,	O
Denmark	O
)	O
.	O

Tus	O
expression	O
was	O
induced	O
by	O
adding	O
2	O
%	O
Galactose	O
(	O
final	O
w/v	O
)	O
for	O
the	O
final	O
2.5	O
h	O
of	O
the	O
G1-arrest	O
.	O

Porphyromonas	O
gingivalis	O
was	O
anaerobically	O
cultured	O
at	O
80	O
%	O
N	O
2	O
,	O
10	O
%	O
CO	O
2	O
,	O
and	O
10	O
%	O
H	O
2	O
at	O
37	O
°C	O
in	O
an	O
anaerobic	B-DEV
chamber	I-DEV
(	O
Concept	B-BRAND
400	I-BRAND
Anaerobic	I-BRAND
Workstation	I-BRAND
;	O
Ruskinn	B-COM
Technology	I-COM
Ltd.	I-COM
,	O
Leeds	O
,	O
UK	O
)	O
in	O
fastidious	O
anaerobe	O
broth	O
(	O
29.7	O
g/L	O
,	O
pH	O
7.2	O
)	O
.	O

The	O
onion	O
epidermal	O
cells	O
then	O
were	O
stained	O
with	O
propidium	O
iodide	O
(	O
10	O
μg/ml	O
)	O
for	O
nuclei	O
and	O
were	O
observed	O
with	O
a	O
Leica	B-BRAND
TCS	I-BRAND
SP2	I-BRAND
AOBS	I-BRAND
confocal	B-DEV
microscope	I-DEV
(	O
Leica	B-COM
Microsystems	I-COM
,	O
Heidelberg	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O


The	O
interaction	O
of	O
OsWRKY13	O
protein	O
with	O
W	O
or	O
W-like	O
box	O
in	O
a	O
promoter	O
region	O
(	O
Supplemental	O
Table	O
3	O
)	O
was	O
examined	O
using	O
a	O
yeast	O
one-hybrid	O
assay	O
according	O
to	O
the	O
manufacturer	O
's	O
protocol	O
(	O
Clontech	B-BRAND
Yeast	I-BRAND
Protocols	I-BRAND
Handbook	I-BRAND
,	O
BD	B-COM
Biosciences	I-COM
Clontech	I-COM
,	O
Mountain	O
View	O
,	O
CA	O
,	O
U.S.A.	O
)	O
.	O

The	O
clinical	O
outcome	O
was	O
evaluated	O
by	O
comparing	O
the	O
preoperative	O
to	O
postoperative	O
best-corrected	O
visual	O
acuity	O
(	O
BCVA	O
)	O
,	O
noncontact	O
specular	O
microscopy	O
(	O
SP3000	B-BRAND
;	O
Topcon	B-COM
Medical	I-COM
Europe	I-COM
BV	I-COM
,	O
Capelle	O
a/d	O
IJssel	O
,	O
The	O
Netherlands	O
)	O
,	O
anterior	O
segment	O
optical	O
coherence	O
tomography	O
(	O
Heidelberg	B-COM
Engineering	I-COM
GmbH	I-COM
,	O
Heidelberg	O
,	O
Germany	O
)	O
,	O
confocal	O
microscopy	O
(	O
Confoscan	B-BRAND
4	I-BRAND
;	O
Nidek	B-COM
Technologies	I-COM
,	O
Padova	O
,	O
Italy	O
)	O
,	O
Scheimpflug	O
imaging	O
(	O
Pentacam	B-BRAND
HR	I-BRAND
;	O
Oculus	B-COM
,	O
Wetzlar	O
,	O
Germany	O
)	O
,	O
and	O
photo-slit-lamp	O
biomicroscopy	O
(	O
Topcon	B-COM
Medical	I-COM
Europe	I-COM
BV	I-COM
)	O
.	O

Photomicrographs	O
were	O
produced	O
using	O
a	O
Zeiss	B-DEV
Axioskop	I-DEV
microscope	I-DEV
(	O
40	O
objective	O
lens	O
)	O
with	O
a	O
digital	B-DEV
camera	I-DEV
(	O
Carl	B-COM
Zeiss	I-COM
GmbH	I-COM
,	O
Jena	O
,	O
Germany	O
)	O
.	O


Cellular	O
ATP	O
content	O
was	O
determined	O
by	O
a	O
luciferin/luciferase	O
assay	O
(	O
Bihler	O
and	O
Jeanrenaud	O
,	O
1970	O
)	O
.	O

Afterwards	O
they	O
were	O
placed	O
in	O
20	O
%	O
EDTA	O
(	O
Sigma	B-COM
Aldrich	I-COM
Chemie	I-COM
GmbH	I-COM
,	O
Steinheim	O
,	O
Germany	O
)	O
for	O
4e5	O
weeks	O
at	O
37	O
C.	O
Decalcification	O
medium	O
was	O
changed	O
every	O
2	O
or	O
3	O
days	O
.	O

All	O
straylight	O
measurements	O
were	O
done	O
using	O
the	O
C-Quant	B-BRAND
(	O
Oculus	B-COM
GmbH	I-COM
,	O
Wetzlar	O
,	O
Germany	O
)	O
,	O
employing	O
the	O
psychophysical	O
compensation	O
comparison	O
method	O
developed	O
by	O
van	O
den	O
Berg	O
.	O

10,11	O
The	O
procedure	O
was	O
similar	O
to	O
those	O
previously	O
reported	O
.	O

12,13	O
The	O
patient	O
was	O
instructed	O
to	O
look	O
through	O
an	O
eyepiece	O
with	O
one	O
eye	O
,	O
while	O
the	O
other	O
eye	O
was	O
patched	O
.	O

The	O
citric	O
acid	O
aerosol	O
,	O
generated	O
by	O
a	O
jet	B-DEV
nebulizer	I-DEV
(	O
PARI	B-BRAND
jet	I-BRAND
nebulizer	I-BRAND
,	O
Paul	O
Ritzau	O
,	O
Pari-Werk	B-COM
GmbH	I-COM
,	O
Germany	O
,	O
output	O
5	O
L	O
s	O
−	O
1	O
,	O
particles	O
mass	O
median	O
diameter	O
1.2	O
í	O
µí	O
1/4	O
‡	O
m	O
)	O
,	O
was	O
delivered	O
to	O
the	O
head	O
chamber	O
of	O
the	O
plethysmograph	O
for	O
3	O
min	O
.	O

BIBO3304	O
was	O
supplied	O
by	O
Boehringer-Ingelheim	B-COM
Pharma	I-COM
GmbH	I-COM
(	O
Rheinland	O
Palatinate	O
,	O
Germany	O
)	O
and	O
L152804	O
was	O
from	O
Banyu	B-COM
(	O
Banyu	B-COM
Pharmaceutical	I-COM
Co.	I-COM
,	I-COM
Ltd.	I-COM
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
arterial	O
blood	O
pressure	O
set	O
was	O
connected	O
,	O
and	O
the	O
transducer	B-DEV
was	O
placed	O
at	O
the	O
level	O
of	O
the	O
heart	O
and	O
zeroed	O
.	O

The	O
LiDCOplus	B-BRAND
monitor	I-BRAND
(	O
LiDCO	B-COM
Ltd.	I-COM
,	O
Cambridge	O
,	O
United	O
Kingdom	O
)	O
26	O
was	O
connected	O
for	O
continuous	O
hemodynamic	O
monitoring	O
.	O

PUK27	O
nOctUria	O
WOrK	O
PrOdUctivity	O
and	O
activity	O
imPairment	O
cOmPared	O
tO	O
Other	O
cOmmOn	O
chrOnic	O
diseases	O
:	O
a	O
systematic	O
revieW	O
Miller	B-BRAND
PS	I-BRAND
1	I-BRAND
,	O
Andersson	O
FL	O
2	O
1	O
MILLER	B-COM
ECONOMICS	I-COM
LTD.	O
,	O
Alderley	O
Edge	O
,	O
UK	O
,	O
2	O
Ferring	B-COM
Pharmaceuticals	I-COM
A/S	I-COM
,	O
Copenhagen	O
,	O
Denmark	O
Objectives	O
:	O
Nocturia	O
is	O
defined	O
by	O
the	O
International	O
Continence	O
Society	O
as	O
the	O
need	O
to	O
void	O
one	O
or	O
more	O
times	O
during	O
the	O
night	O
,	O
with	O
each	O
of	O
the	O
voids	O
preceded	O
and	O
followed	O
by	O
sleep	O
.	O

Nutritional	O
protocol	O
All	O
infants	O
were	O
fed	O
with	O
their	O
own	O
mothers	O
'	O
milk	O
or	O
donated	O
human	O
milk	O
,	O
fortified	O
with	O
5	O
%	O
FM	O
85	O
(	O
Nestlé	B-COM
,	O
Munich	O
,	O
Germany	O
)	O
,	O
or	O
preterm	O
formula	O
(	O
Humana	B-BRAND
0	I-BRAND
,	O
Humana	B-COM
GmbH	I-COM
,	O
Herford	O
,	O
Germany	O
)	O
.	O

Parenteral	O
nutrition	O
was	O
started	O
in	O
infants	O
b	O
1000	O
g	O
on	O
day	O
3	O
with	O
aminoacids	O
,	O
lipids	O
(	O
Aminopäd	B-BRAND
10	I-BRAND
%	I-BRAND
,	O
Intralipid	B-BRAND
20	I-BRAND
%	I-BRAND
,	O
Baxter	B-COM
,	O
Erlangen	O
,	O
Germany	O
)	O
trace	O
elements	O
and	O
vitamins	O
(	O
Peditrace	B-BRAND
,	O
Soluvit	B-BRAND
N	I-BRAND
,	O
Vitintra	B-BRAND
,	O
Pharmacia-Upjohn	B-COM
GmbH	I-COM
,	O
Erlangen	O
,	O
Germany	O
)	O
.	O

Husbandry	O
and	O
apparent	O
metabolisable	O
energy	O
determination	O
Ross	O
308	O
female	O
chickens	O
were	O
obtained	O
from	O
a	O
commercial	O
hatchery	O
(	O
Grampian	B-COM
Ltd	I-COM
,	O
Whitburn	O
,	O
UK	O
)	O
at	O
1-d-old	O
and	O
were	O
placed	O
in	O
a	O
single	O
floor	O
pen	O
at	O
32	O
C.	O
DNA	O
was	O
extracted	O
by	O
the	O
method	O
of	O
Reguant	O
and	O
Bordons	O
(	O
2003	O
)	O
and	O
16S	O
rDNA	O
gene	O
was	O
amplified	O
in	O
a	O
thermocycler	B-DEV
(	O
Techne	B-COM
LTD	I-COM
,	O
Cambridge	O
,	O
UK	O
)	O
using	O
the	O
primers	O
FD1	O
(	O
5	O
0	O
CAACAGAGTTTGATCCTGGCTCAG	O
3	O
0	O
)	O
and	O
RD1	O
(	O
5	O
0	O
GCTTAAGGAGGTGATCCAGCC	O
3	O
0	O
)	O
designed	O
by	O
Weisburg	O
et	O
al.	O
(	O
1991	O
)	O
.	O

Protein	O
extraction	O
and	O
Western	O
blot	O
The	O
VP	O
was	O
homogenized	O
using	O
a	O
Micro	B-BRAND
Dismembrator	I-BRAND
(	O
B.	B-COM
Braun	I-COM
Biotech	I-COM
International	I-COM
GmbH	I-COM
,	O
Melsungen	O
,	O
Germany	O
)	O
at	O
2000	O
rpm	O
for	O
45	O
sec	O
.	O

Tissues	O
were	O
then	O
added	O
to	O
an	O
adequate	O
amount	O
of	O
lysis	O
buffer	O
containing	O
either	O
0.5	O
%	O
Nonidet	O
P-40	O
(	O
NP-40	O
;	O
mice	O
tissues	O
)	O
,	O
0.5	O
%	O
NaDOC	O
,	O
0.1	O
%	O
SDS	O
,	O
50	O
mm	O
Tris-HCl	O
(	O
pH	O
7.5	O
)	O
,	O
150	O
mm	O
NaCl	O
,	O
1	O
mm	O
EDTA	O
(	O
pH	O
8.0	O
)	O
,	O
1	O
mm	O
NaF	O
,	O
and	O
Complete	B-BRAND
Protease	I-BRAND
Inhibitor	I-BRAND
Cocktail	I-BRAND
(	O
Roche	B-COM
Molecular	I-COM
Biochemicals	O
,	O
Mannheim	O
,	O
Germany	O
)	O
,	O
or	O
alternatively	O
,	O
7	O
m	O
urea	O
(	O
rat	O
tissues	O
)	O
,	O
2	O
m	O
thio-urea	O
,	O
4	O
%	O
3	O
-	O
[	O
(	O
3-cholamidopropyl	O
)	O
dimethylammonio	O
]-	O
-1	O
propanesulfonate	O
,	O
and	O
30	O
mm	O
Tris	O
(	O
pH	O
8.5	O
)	O
.	O

Laser	O
Doppler	O
perfusion	O
imaging	O
Skin	O
microvascular	O
perfusion	O
was	O
measured	O
at	O
the	O
drug	O
delivery	O
site	O
using	O
a	O
laser	B-DEV
Doppler	I-DEV
imager	I-DEV
(	O
MoorLDI	B-BRAND
,	O
Moor	B-COM
Instruments	I-COM
Ltd	I-COM
,	O
Devon	O
,	O
UK	O
)	O
.	O

A	O
2	O
mW	O
helium-neon	B-DEV
laser	I-DEV
scans	O
the	O
surface	O
of	O
the	O
skin	O
,	O
and	O
light	O
back-scattered	O
from	O
moving	O
erythrocytes	O
is	O
F	O
.	O

The	O
average	O
size	O
and	O
size	O
distribution	O
of	O
the	O
dry	O
nanoparticles	O
were	O
determined	O
by	O
measuring	O
the	O
diameter	O
of	O
more	O
than	O
100	O
particles	O
with	O
the	O
image	B-DEV
analysis	I-DEV
software	I-DEV
AnalySIS	B-BRAND
Auto	I-BRAND
(	O
Soft	B-COM
Imaging	I-COM
System	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

Hydrodynamic	O
diameter	O
and	O
size	O
distribution	O
of	O
the	O
nanoparticles	O
dispersed	O
in	O
an	O
aqueous	O
phase	O
were	O
measured	O
using	O
a	O
particle	B-DEV
analyzer	I-DEV
,	O
model	O
NANOPHOX	B-BRAND
(	O
Sympatec	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

Lowary	O
(	O
University	O
of	O
Alberta	O
)	O
.	O

L7	O
,	O
MW	O
707.63	O
Da	O
)	O
were	O
purchased	O
from	O
IsoSep	B-COM
AB	I-COM
(	O
Sweden	O
)	O
.	O

The	O
structure	O
of	O
each	O
ligand	O
is	O
shown	O
in	O
Figure	O
S1	O
in	O
the	O
Supporting	O
Information	O
.	O

Half	O
of	O
each	O
supernatant	O
was	O
incubated	O
overnight	O
at	O
378C	O
with	O
an	O
equal	O
volume	O
of	O
pH	O
4.5	O
buffer	O
(	O
0.2	O
M	O
sodium	O
acetate	O
)	O
in	O
the	O
presence	O
of	O
10	O
U	O
almond	O
b-glucosidase	O
EC	O
3.2.1.21	O
(	O
NBS	B-COM
Biologicals	I-COM
Ltd.	I-COM
,	O
Huntingdon	O
,	O
UK	O
)	O
.	O

The	O
two	O
sample	O
fractions	O
were	O
each	O
partitioned	O
at	O
pH	O
2	O
against	O
an	O
equal	O
volume	O
of	O
ethylacetate	O
,	O
which	O
was	O
back	O
washed	O
against	O
H	O
2	O
O	O
and	O
then	O
reduced	O
to	O
dryness	O
by	O
rotary	O
evaporation	O
at	O
258C	O
.	O

Cells	O
were	O
counted	O
on	O
a	O
semi	B-DEV
automated	I-DEV
microcell	I-DEV
counter	I-DEV
(	O
F-800	B-BRAND
;	O
Sysmex	B-COM
GmbH	I-COM
,	O
Norderstedt	O
,	O
Germany	O
)	O
using	O
the	O
instructions	O
of	O
the	O
manufacturer	O
.	O

PGFE	O
PFGE	O
was	O
performed	O
using	O
the	O
previously	O
described	O
protocol	O
for	O
Salmonella	O
[	O
7,37	O
]-	O
with	O
modifications	O
:	O
Strains	O
were	O
cultured	O
overnight	O
at	O
30	O
°C	O
on	O
R1-agar	O
and	O
suspended	O
in	O
CBS-buffer	O
(	O
100	O
mM	O
Tris	O
:	O
100	O
MM	O
EDTA	O
,	O
pH	O
8.0	O
)	O
to	O
a	O
final	O
turbidity	O
of	O
0.38-0.39	O
at	O
A	O
480	O
.	O

Lysozyme	O
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
was	O
added	O
to	O
the	O
400	O
μl	O
bacterial	O
suspensions	O
to	O
reach	O
a	O
final	O
concentration	O
of	O
1	O
mg/ml	O
.	O

In	O
this	O
context	O
,	O
consideration	O
could	O
probably	O
be	O
given	O
to	O
meeting	O
the	O
needs	O
of	O
patient	O
subpopulations	O
with	O
a	O
particular	O
disease	O
modality	O
that	O
is	O
best	O
treated	O
by	O
inhalation	O
,	O
as	O
has	O
begun	O
recently	O
with	O
a	O
range	O
of	O
different	O
jet	B-DEV
nebulizers	I-DEV
designed	O
with	O
features	O
specifically	O
for	O
use	O
by	O
infants	O
,	O
toddlers	O
and	O
preschool	O
children	O
(	O
LC	B-BRAND
®	I-BRAND
-	I-BRAND
Sprint	I-BRAND
,	O
PARI	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

Efforts	O
are	O
also	O
continuing	O
to	O
develop	O
marketable	O
inhaled	O
insulin	O
for	O
systemic	O
delivery	O
by	O
inhalation	O
despite	O
the	O
failure	O
of	O
Exubera	B-BRAND
in	O
2007	O
,	O
and	O
the	O
use	O
of	O
the	O
lungs	O
as	O
a	O
gateway	O
organ	O
for	O
delivery	O
to	O
targets	O
elsewhere	O
in	O
the	O
body	O
will	O
probably	O
continue	O
.	O

Each	O
reaction	O
consists	O
of	O
2	O
µl	O
template	O
DNA	O
,	O
0.5	O
µl	O
of	O
each	O
primers	O
at	O
25	O
µM	O
,	O
1.25	O
µl	O
of	O
dNTP	O
(	O
BIORON	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
at	O
5	O
mM	O
,	O
0.5	O
U	O
Taq	B-BRAND
DNA	I-BRAND
polymerase	I-BRAND
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
and	O
5	O
µl	O
10	O
×	O
PCR	O
buffer	O
.	O

All	O
the	O
blood	O
pressure	O
measurements	O
were	O
undertaken	O
with	O
an	O
automatic	O
oscillometric	B-DEV
blood	I-DEV
pressure	I-DEV
recorder	I-DEV
(	O
Dinamap	B-BRAND
,	O
Critikon	B-COM
Ltd	I-COM
,	O
Ascot	O
,	O
UK	O
)	O
.	O

The	O
resting	O
blood	O
pressure	O
was	O
measured	O
three	O
times	O
at	O
1-min	O
intervals	O
from	O
the	O
right	O
arm	O
after	O
the	O
patient	O
had	O
been	O
seated	O
for	O
at	O
least	O
5	O
min	O
.	O

Airflows	O
were	O
set	O
to	O
700	O
l/min	O
and	O
250	O
l/min	O
in	O
the	O
larger	O
and	O
the	O
smaller	O
chambers	O
,	O
respectively	O
(	O
Promethion	B-BRAND
FG	I-BRAND
1000	I-BRAND
and	O
FG	B-BRAND
250	I-BRAND
flow	B-DEV
generators	I-DEV
;	O
Sable	B-COM
Systems	I-COM
Europe	I-COM
GmbH	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

Chambers	O
were	O
operated	O
under	O
negative	O
pressure	O
(	O
−	O
60	O
Pa	O
)	O
compared	O
with	O
ambient	O
air	O
pressure	O
.	O

The	O
crystalline	O
status	O
was	O
determined	O
using	O
the	O
Di	B-DEV
erential	I-DEV
Scanning	I-DEV
Calorimeter	I-DEV
(	O
TA	B-BRAND
8500	I-BRAND
,	O
Mettler	B-COM
Toledo	I-COM
GmbH	I-COM
,	O
Gieû	O
en	O
,	O
Germany	O
)	O
.	O

Approximately	O
15	O
mg	O
of	O
the	O
samples	O
were	O
weighted	O
in	O
small	O
aluminium	B-DEV
pans	I-DEV
and	O
heated	O
from	O
258C	O
to	O
858C	O
with	O
a	O
scan	O
rate	O
of	O
5	O
K/min	O
.	O


,	O
Alken	O
,	O
Belgium	O
)	O
and	O
loaded	O
into	O
the	O
freeze	B-DEV
dryer	I-DEV
(	O
Model	O
Lyovac	B-BRAND
GT4	I-BRAND
,	O
GEA	B-COM
Lyophil	I-COM
GmbH	I-COM
,	I-COM
Hürth	O
,	O
Germany	O
)	O
.	O

Vials	O
were	O
frozen	O
to	O
−	O
35	O
°C	O
in	O
2	O
h.	O
Primary	O
drying	O
(	O
50	O
h	O
)	O
was	O
started	O
at	O
a	O
shelf	O
temperature	O
of	O
−	O
35	O
°C	O
and	O
a	O
chamber	O
pressure	O
of	O
0.4	O
mbar	O
.	O

Additionally	O
,	O
for	O
blocking	O
of	O
the	O
binding	O
of	O
antibodies	O
to	O
the	O
Fc	O
receptors	O
,	O
the	O
FcR	O
Blocking	O
Reagent	O
(	O
human	O
from	O
Miltenyi	B-COM
Biotec	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
,	O
in	O
dilution	O
1:100	O
,	O
for	O
10	O
min	O
at	O
+4	O
°C	O
,	O
was	O
used	O
on	O
all	O
studied	O
sections	O
.	O

To	O
apply	O
uniaxial	O
strain	O
to	O
the	O
protein	O
film	O
,	O
one	O
T-piece	O
is	O
connected	O
to	O
a	O
piezoelectric	B-DEV
motor	I-DEV
unit	I-DEV
(	O
IW-801	B-BRAND
,	O
Inchworm	O
single	O
axis	O
,	O
EXFO	B-COM
Burleigh	I-COM
,	O
Mississauga	O
,	O
Ontario	O
,	O
Canada	O
)	O
equipped	O
with	O
an	O
integral	B-DEV
encoder	I-DEV
stage	I-DEV
(	O
TSE-150	B-BRAND
,	O
Exfo	B-COM
Burleigh	I-COM
)	O
attached	O
to	O
an	O
incremental	B-DEV
linear	I-DEV
encoder	I-DEV
(	O
EXE	B-BRAND
650B	I-BRAND
,	O
Dr.	B-COM
Johannes	I-COM
Heidenhain	I-COM
GmbH	I-COM
,	O
Traunreut	O
,	O
Germany	O
)	O
.	O

The	O
absolute	O
accuracy	O
of	O
stage	O
and	O
encoder	O
is	O
1	O
µm	O
.	O

Confocal	O
laser	O
scanning	O
microscopic	O
imaging	O
was	O
performed	O
using	O
a	O
Leica	O
confocal	B-DEV
microscope	I-DEV
(	O
TCSSPE	B-BRAND
,	O
Leica	B-COM
Microsystems	I-COM
CMS	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
.	O

Statistical	O
assay	O
Student	O
's	O
t-test	O
and	O
Fisher	O
's	O
exact	O
test	O
were	O
used	O
for	O
statistical	O
analysis	O
.	O

Pen-like	O
devices	O
(	O
Sniffin	B-BRAND
'	B-BRAND
Sticks	I-BRAND
;	O
Burghart	B-COM
Gmbh	I-COM
,	O
Germany	O
)	O
were	O
filled	O
with	O
7	O
mL	O
of	O
each	O
diluted	O
solution	O
and	O
coded	O
with	O
a	O
three-digit	O
number	O
.	O

The	O
proteins	O
were	O
purified	O
to	O
>	O
95	O
%	O
by	O
HPLC	O
using	O
a	O
Vydac	B-BRAND
®	B-BRAND
reverse	I-BRAND
phase	I-BRAND
HPLC	I-BRAND
C4	I-BRAND
Mass	I-BRAND
Spec	I-BRAND
214MS54	I-BRAND
column	O
(	O
Grace	B-COM
Silica	I-COM
GmbH	I-COM
,	O
Düren	O
,	O
Germany	O
)	O
.	O

NMR	O
data	O
acquisition	O
The	O
mutants	O
of	O
ubiquitin	O
samples	O
were	O
prepared	O
for	O
NMR	O
experiments	O
by	O
subsequent	O
dialysis	O
against	O
50	O
mM	O
sodium	O
phosphate	O
buffer	O
at	O
pH	O
5.8	O
(	O
90	O
%	O
H	O
2	O
O	O
,	O
10	O
%	O
D	O
2	O
O	O
)	O
.	O

RNA	O
Extraction	O
and	O
Real	O
Time	O
RT-PCR	O
Screening	O
of	O
the	O
Samples	O
In	O
the	O
laboratory	O
,	O
the	O
samples	O
were	O
vortex-mixed	O
and	O
centrifuged	O
at	O
1000	O
rpm	O
for	O
10	O
min	O
following	O
which	O
140	O
ml	O
of	O
supernatant	O
was	O
used	O
for	O
the	O
extraction	O
of	O
viral	O
RNA	O
using	O
commercially	O
available	O
QIAamp	B-BRAND
Viral	I-BRAND
RNA	I-BRAND
Mini	I-BRAND
Kit	B-DEV
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
as	O
per	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Transwells	B-BRAND
were	O
mounted	O
with	O
DAPI	O
fluorescent	O
mounting	O
media	O
(	O
Vector	B-COM
Laboratories	I-COM
Ltd.	I-COM
,	O
Peterborough	O
,	O
UK	O
)	O
and	O
left	O
overnight	O
at	O
4	O
°C	O
before	O
analysis	O
using	O
a	O
spinning	B-DEV
disk	I-DEV
confocal	I-DEV
microscope	I-DEV
with	O
Volocity	B-BRAND
software	I-BRAND
(	O
Version	O
5.5	O
,	O
PerkinElmer	B-COM
,	O
Cambridge	O
,	O
UK	O
)	O
.	O


,	O
USA	O
)	O
,	O
1	O
%	O
Penicillin-Streptomycin	O
(	O
PAA	B-COM
,	B-COM
Laboratories	I-COM
GmbH	I-COM
,	O
Austria	O
)	O
and	O
1	O
%	O
Amphotericin	O
B	O
(	O
PAA	B-COM
,	B-COM
Laboratories	I-COM
GmbH	I-COM
,	O
Austria	O
)	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
°C	O
in	O
95	O
%	O
relative	O
humidified	O
atmosphere	O
containing	O
5	O
%	O
CO	O
2	O
.	O

A	O
Nikon	B-BRAND
Ti-E	I-BRAND
microscope	I-BRAND
Nikon	B-COM
Instruments	I-COM
Europe	I-COM
B.V.	I-COM
,	O
Amstelveen	O
,	O
The	O
Netherlands	O
,	O
equipped	O
with	O
an	O
APO-TIRFM	B-DEV
lens	I-DEV
60	I-DEV
,	O
numerical	O
aperture	O
of	O
1.49	O
with	O
oil	O
immersion	O
,	O
working	O
distance	O
of	O
0.12	O
mm	O
,	O
and	O
refractive	O
index	O
of	O
immersion	O
oil	O
of	O
1.51	O
was	O
used	O
along	O
with	O
a	O
TIRFM	B-DEV
laser	I-DEV
beam	I-DEV
position	I-DEV
manipulator	I-DEV
controlled	O
using	O
the	O
``	O
NIKON	B-BRAND
TI	I-BRAND
CONTROL	I-BRAND
''	O
software	B-DEV
.	O

Samples	O
from	O
liver	O
,	O
kidney	O
,	O
gills	O
,	O
head	O
kidney	O
,	O
skin	O
,	O
adipose	O
tissue	O
,	O
heart	O
and	O
dorsal	O
fin	O
were	O
sliced	O
and	O
immediately	O
placed	O
in	O
RNAlater	O
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
,	O
following	O
the	O
supplier	O
's	O
protocol	O
.	O

Animals	O
for	O
the	O
stocking	O
density	O
experiment	O
were	O
bred	O
in	O
a	O
recirculation	O
system	O
with	O
brackish	O
water	O
in	O
the	O
Institute	O
for	O
Fisheries	O
in	O
Born	O
,	O
Germany	O
.	O

Fungal	O
genomic	O
DNA	O
was	O
isolated	O
as	O
described	O
by	O
Cenis	O
(	O
1992	O
)	O
and	O
plasmid	O
DNA	O
was	O
isolated	O
using	O
a	O
plasmid	B-BRAND
DNA	I-BRAND
preparation	I-BRAND
kit	I-BRAND
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Fungal	O
genomic	O
DNA	O
and	O
lambda	O
DNA	O
was	O
transferred	O
to	O
Amersham	B-BRAND
Hybond-N	I-BRAND
+	I-BRAND
filters	I-BRAND
(	O
GE	B-COM
Healthcare	I-COM
Limited	I-COM
,	O
Freiburg	O
,	O
Germany	O
)	O
after	O
digestion	O
with	O
restriction	O
enzymes	O
and	O
size	O
separation	O
on	O
a	O
1	O
%	O
agarose	O
gel	O
according	O
to	O
Sambrook	O
and	O
associates	O
(	O
1989	O
)	O
.	O

Each	O
time	O
,	O
the	O
wooden	O
cylinders	O
were	O
presented	O
to	O
the	O
investigators	O
in	O
randomized	O
order	O
based	O
on	O
a	O
random	O
treatment	O
allocation	O
plan	O
generated	O
before	O
initiation	O
of	O
the	O
trial	O
by	O
using	O
the	O
random	O
number	O
function	O
of	O
Excel	B-BRAND
(	O
Microsoft	B-BRAND
Office	I-BRAND
2003	I-BRAND
,	O
Microsoft	B-COM
Deutschland	I-COM
GmbH	I-COM
,	O
Munich	O
,	O
Germany	O
)	O
.	O

The	O
investigators	O
were	O
divided	O
into	O
2	O
groups	O
.	O

Surgical	O
Results	O
All	O
patients	O
had	O
a	O
TMD	O
as	O
described	O
by	O
Regan	O
et	O
aP	O
and	O
Rosenthal	O
et	O
al	O
,	O
'	O
''	O
*	O
using	O
30	B-DEV
°	B-DEV
optics	I-DEV
(	O
Karl	B-COM
Storz	I-COM
GmbH	I-COM
&	I-COM
Co.	I-COM
,	O
Tuttlingen	O
,	O
Germany	O
)	O
and	O
a	O
pneumatic	B-DEV
arm	I-DEV
holding	O
the	O
endoscope	B-DEV
(	O
Geyser	B-COM
S.A.	I-COM
,	O
Coudes	O
,	O
France	O
)	O
.	O

Finally	O
,	O
NR	O
was	O
extracted	O
from	O
the	O
lysosomes	O
using	O
400	O
μL	O
of	O
an	O
extraction	O
solution	O
(	O
1	O
%	O
v/v	O
acetic	O
acid	O
and	O
50	O
%	O
v/v	O
ethanol	O
)	O
and	O
gently	O
shaken	O
on	O
a	O
horizontal	B-DEV
shaker	I-DEV
(	O
TiMix	B-BRAND
2	I-BRAND
,	O
Johanna	B-COM
Otto	I-COM
GmbH	I-COM
,	O
Hechingen	O
,	O
Germany	O
)	O
for	O
10	O
min	O
.	O

NR	O
fluorescence	O
was	O
measured	O
at	O
excitation/emission	O
wavelengths	O
of	O
530/645	O
nm	O
using	O
the	O
same	O
plate	B-DEV
reader	I-DEV
.	O

The	O
oil	O
and	O
aqueous	O
phases	O
were	O
then	O
mixed	O
together	O
108	O
with	O
an	O
UltraTurrax	B-BRAND
®	I-BRAND
T25	I-BRAND
homogeniser	I-BRAND
(	O
IKA	B-COM
®	I-COM
-	I-COM
Werke	I-COM
GmbH	I-COM
&	I-COM
Co.	I-COM
.	I-COM


In	O
order	O
to	O
109	O
avoid	O
bias	O
the	O
order	O
of	O
preparation	O
of	O
the	O
batches	O
was	O
random	O
.	O

110	O
Droplet	O
size	O
analysis	O
111	O
The	O
emulsions	O
were	O
analyzed	O
for	O
droplet	O
size	O
using	O
an	O
optical	B-DEV
microscope	I-DEV
equipped	O
with	O
an	O
USB	B-DEV
112	I-DEV
video	I-DEV
camera	I-DEV
(	O
Bresser	B-COM
,	O
Germany	O
)	O
.	O

Data	O
Coding	O
Visual	O
attention	O
to	O
the	O
video	O
during	O
the	O
learning	O
phase	O
and	O
the	O
recognition	O
memory	O
tests	O
was	O
analyzed	O
using	O
SMI	B-BRAND
BeGaze	I-BRAND
software	I-BRAND
(	O
SensoMotoric	B-COM
Instruments	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

In	O
the	O
current	O
literature	O
,	O
there	O
is	O
no	O
standard	O
definition	O
for	O
fixations	O
,	O
which	O
have	O
been	O
defined	O
as	O
anywhere	O
between	O
50	O
and	O
250	O
ms	O
(	O
for	O
discussion	O
,	O
see	O
Holmqvist	O
et	O
al.	O
,	O
2011	O
)	O
.	O

Physiological	O
experiments	O
were	O
performed	O
in	O
50	O
ml	O
minimal	O
medium	O
(	O
pH	O
5.2	O
)	O
containing	O
1.6	O
g	O
l	O
-1	O
NH	O
4	O
Cl	O
,	O
0.5	O
g	O
l	O
-1	O
KH	O
2	O
PO	O
4	O
,	O
0.2	O
g	O
l	O
-1	O
MgSO	O
4	O
,	O
0.17	O
g	O
l	O
-1	O
FeSO	O
4	O
and	O
20	O
g	O
l	O
-1	O
of	O
varying	O
carbon	O
sources	O
such	O
as	O
xylan	O
from	O
birch	B-DEV
wood	I-DEV
(	O
Carl	B-COM
Roth	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
,	O
glucose	O
and	O
xylose	O
in	O
500	O
ml	O
Erlenmeyer	B-DEV
flasks	I-DEV
at	O
28	O
°C	O
and	O
150	O
rpm	O
.	O

The	O
total	O
crude	O
fat	O
in	O
MPI	O
was	O
determined	O
from	O
freeze-dried	O
MPI	O
by	O
extracting	O
approximately	O
1.0	O
g	O
of	O
the	O
dry	O
MPI	O
with	O
20	O
mL	O
of	O
petroleum	O
ether	O
for	O
4	O
h	O
using	O
a	O
Soxtec	B-BRAND
1043	I-BRAND
extraction	I-BRAND
unit	I-BRAND
(	O
Tecator	B-COM
AB	I-COM
,	O
Höganäs	O
,	O
Sweden	O
)	O
.	O

After	O
extraction	O
,	O
the	O
solvent	O
was	O
evaporated	O
at	O
21	O
°C	O
in	O
a	O
fume	O
hood	O
.	O

BSEP	O
antibodies	O
were	O
raised	O
in	O
the	O
rabbit	O
and	O
generated	O
by	O
the	O
antibody	O
generation	O
group	O
at	O
AstraZeneca	B-COM
Ltd.	I-COM
,	O
UK	O
(	O
antibody	O
clone	O
H3310	O
)	O
and	O
used	O
at	O
a	O
dilution	O
of	O
1:50	O
.	O

Nodules	O
and	O
other	O
major	O
cell	O
aggregates	O
were	O
visualized	O
as	O
dark	O
spots	O
before	O
a	O
clear	O
background	O
using	O
an	O
electronic	B-DEV
camera	I-DEV
system	I-DEV
(	O
Phase	B-COM
GmbH	I-COM
,	O
Lübeck	O
,	O
Germany	O
)	O
operating	O
at	O
maximum	O
contrast	O
.	O

Spot	O
staining	O
was	O
quantified	O
using	O
Gel-Pro	B-BRAND
Analyzer	I-BRAND
3.1	I-BRAND
software	I-BRAND
(	O
Media	B-COM
Cybernetics	I-COM
,	O
Silver	O
Spring	O
,	O
MD	O
,	O
USA	O
)	O
.	O

Spatial	O
co-ordinates	O
for	O
the	O
determination	O
of	O
kinematic	O
data	O
were	O
collected	O
using	O
an	O
ultrasound-based	B-BRAND
zebris	I-BRAND
CMS-HS	I-BRAND
system	I-BRAND
(	O
ZEBRIS	B-COM
,	O
Medizintechnik	O
GmbH	O
,	O
Germany	O
)	O
.	O

The	O
measuring	O
heads	O
were	O
positioned	O
behind	O
the	O
individual	O
(	O
Fig.	O
1	O
)	O
.	O

Gas	O
concentration	O
(	O
SF	O
6	O
and	O
CH	O
4	O
)	O
in	O
breath	O
and	O
ambient	O
air	O
was	O
determined	O
using	O
a	O
gas	B-DEV
chromatograph	I-DEV
(	O
CP-9003	B-BRAND
,	O
Varian-Chrompack	B-COM
,	O
Les	O
Ulis	O
,	O
France	O
)	O
fitted	O
with	O
an	O
electron	B-DEV
capture	I-DEV
detector	I-DEV
(	O
Autosystem	B-BRAND
XL	I-BRAND
,	O
Perkin	B-COM
Elmer	I-COM
Instruments	I-COM
,	O
Courtaboeuf	O
,	O
France	O
)	O
equipped	O
with	O
a	O
Molecular	B-DEV
Sieve	I-DEV
0.5-nm	I-DEV
column	I-DEV
(	O
3	O
m	O
×	O
3.2	O
mm	O
i.d	O
;	O
Interchim	B-COM
,	O
Montluçon	O
,	O
France	O
)	O
maintained	O
at	O
50	O
°C	O
for	O
SF	O
6	O
,	O
or	O
fitted	O
with	O
a	O
flame-ionization	B-DEV
detector	I-DEV
and	O
equipped	O
with	O
a	O
Porapak	B-BRAND
N	I-BRAND
80-100	I-BRAND
mesh	I-BRAND
column	I-BRAND
(	O
3	O
m	O
×	O
3.2	O
mm	O
i.d.	O
;	O
Alltech	B-COM
France	I-COM
SARL	I-COM
,	O
Templemars	O
,	O
France	O
)	O
maintained	O
at	O
40	O
°C	O
for	O
CH	O
4	O
.	O

The	O
flow	O
rate	O
of	O
the	O
carrier	B-DEV
gas	I-DEV
was	O
30	O
mL/min	O
of	O
N	O
2	O
for	O
SF	O
6	O
and	O
40	O
mL/min	O
of	O
helium	O
for	O
CH	O
4	O
.	O

Due	O
to	O
technical	O
faults	O
we	O
lost	O
or	O
disregarded	O
as	O
evident	O
outliers	O
the	O
measurements	O
of	O
PTR-ToF-MS	O
Analysis	O
Measurements	O
were	O
performed	O
with	O
a	O
commercial	O
PTR-ToF	B-DEV
8000	I-DEV
instrument	O
(	O
Ionicon	B-COM
Analytik	I-COM
GmbH	I-COM
,	O
Innsbruck	O
,	O
Austria	O
)	O
with	O
the	O
Time	O
of	O
Flight	O
analyser	O
operated	O
in	O
V	O
mode	O
.	O

The	O
instrument	O
was	O
an	O
Elzone	B-BRAND
model	I-BRAND
8OXY	I-BRAND
(	O
Particle	B-COM
Data	I-COM
Ltd.	I-COM
,	O
Cheltenham	O
,	O
Gloucs.	O
,	O
UK	O
)	O
.	O

The	O
analyzer	B-DEV
was	O
fitted	O
with	O
a	O
30-pm	O
orifice	O
tube	O
and	O
calibrated	O
using	O
latex	O
standards	O
of	O
sizes	O
2.02	O
,	O
5.00	O
,	O
and	O
10.18	O
p	O
m	O
to	O
give	O
a	O
size	O
range	O
1.00-15.01	O
p	O
m	O
divided	O
into	O
128	O
channels	O
.	O

Statistical	O
analysis	O
Multivariate	O
analysis	O
:	O
OPLS-DA	O
Orthogonal	O
projections	O
to	O
latent	O
structures	O
discriminant	O
analysis	O
(	O
OPLS-DA	O
)	O
was	O
performed	O
in	O
SIMCA-P	B-BRAND
?	O

12.0	O
(	O
Umetrics	B-COM
AB	I-COM
,	O
Umeå	O
,	O
Sweden	O
)	O
on	O
mean	O
centered	O
and	O
unit	O
variance	O
scaled	O
metabolite	O
responses	O
from	O
the	O
original	O
data	O
set	O
.	O

To	O
visualize	O
double-stranded	O
DNA	O
,	O
sections	O
were	O
counterstained	O
with	O
DAPI	O
(	O
10236276001	O
,	O
1:1,000	O
)	O
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
for	O
10	O
min	O
.	O

Finally	O
,	O
sections	O
were	O
mounted	O
with	O
glass	O
coverslips	O
using	O
Fluorescent	O
Mounting	O
Medium	O
(	O
DAKO	B-COM
Ltd	I-COM
,	O
Cambridgeshire	O
,	O
UK	O
)	O
.	O

Flow	O
cytometry	O
was	O
performed	O
on	O
a	O
Dako	B-BRAND
CyAn	I-BRAND
ADP	B-DEV
platform	I-DEV
(	O
Beckman-Coulter	B-COM
Ltd.	I-COM
,	O
UK	O
)	O
and	O
analyzed	O
using	O
Summit	B-BRAND
v4	I-BRAND
.3	I-BRAND
software	B-DEV
.	O

Isolation	O
and	O
culture	O
of	O
BMDC/BMM	O
BMDC	O
were	O
prepared	O
by	O
culturing	O
bone	O
marrow	O
cells	O
obtained	O
from	O
the	O
femurs	O
and	O
tibia	O
of	O
mice	O
in	O
RPMI	O
1640	O
medium	O
in	O
the	O
presence	O
of	O
granulocyte	O
macrophage-colony	O
stimulating	O
factor	O
(	O
GM-CSF	O
)	O
(	O
50	O
ng/mL	O
)	O
.	O

For	O
chromatography	O
,	O
heparin-agarose	O
was	O
purchased	O
from	O
Sigma	B-COM
,	O
and	O
diethylaminoethyl	O
(	O
DEAE	O
)	O
-	O
Sephacel	O
and	O
carboxymethyl	O
(	O
CM	O
)	O
-	O
Sepharose	O
were	O
purchased	O
from	O
Pharmacia	B-COM
AB	I-COM
(	O
Uppsala	O
,	O
Sweden	O
)	O
.	O

For	O
immunohistochemical	O
staining	O
,	O
an	O
avidin-biotin-horseradish	B-DEV
peroxidase	I-DEV
complex	I-DEV
system	I-DEV
(	O
Vectastain	B-BRAND
,	O
Vector	B-COM
Lab.	I-COM
,	O
Burlingame	O
,	O
CA	O
)	O
was	O
used	O
with	O
3,3	O
'	O
-	O
diaminobenzidine	O
as	O
substrate	O
;	O
specific	O
rabbit	O
polyclonal	O
antibody	O
for	O
HBGF-1	O
(	O
no.	O
06-101	O
)	O
was	O
purchased	O
from	O
Upstate	B-COM
Biotechnology	I-COM
(	O
Lake	O
Placid	O
,	O
NY	O
)	O
;	O
and	O
specific	O
rabbit	O
polyclonal	O
antibody	O
for	O
HBGF-2	O
was	O
obtained	O
from	O
A.	O
NIR	O
fluorescence	O
emission	O
at	O
700	O
nm	O
was	O
collected	O
and	O
detected	O
with	O
a	O
fast	B-DEV
photomultiplier	I-DEV
tube	I-DEV
(	O
Hamamatsu	B-COM
,	O
Japan	O
)	O
and	O
time-correlated	O
single	B-DEV
photon	I-DEV
counting	I-DEV
system	I-DEV
(	O
Becker	B-COM
and	I-COM
Hickl	I-COM
GmbH	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
.	O

In	O
vivo	O
magnetic	O
resonance	O
images	O
were	O
obtained	O
using	O
a	O
MRI	B-DEV
scanner	I-DEV
at	O
3.0-T	O
field	O
strength	O
(	O
Tim	B-BRAND
Trio	I-BRAND
;	O
Siemens	B-COM
,	O
Erlangen	O
,	O
Germany	O
)	O
,	O
after	O
the	O
probe	O
was	O
intravenously	O
injected	O
into	O
the	O
mice	O
prepared	O
as	O
described	O
above	O
.	O

Animals	O
received	O
humane	O
care	O
in	O
compliance	O
with	O
the	O
Principles	O
of	O
Laboratory	O
Animal	O
Care	O
formuAnimals	O
were	O
premedicated	O
with	O
an	O
intramuscular	O
injection	O
of	O
0.1-0.5	O
mg/kg	O
xylazin	O
(	O
Rompun	O
2	O
%	O
,	O
Bayer	O
lated	O
by	O
the	O
National	O
Society	O
for	O
Medical	O
Research	O
and	O
the	O
Guide	O
for	O
the	O
Care	O
and	O
Use	O
of	O
Laboratory	O
Animals	O
Vital	O
GmbH	O
,	O
Leverkusen	O
,	O
Germany	O
)	O
and	O
10-20	O
mg/kg	O
Ketamin	O
10	O
%	O
(	O
Bela-Pharm	O
GmbH	O
&	O
Co.	O
.	O

The	O
ability	O
of	O
the	O
fibroblasts	O
to	O
contract	O
the	O
floating	O
gels	O
was	O
determined	O
by	O
quantifying	O
the	O
area	O
of	O
the	O
gels	O
daily	O
using	O
an	O
LAS4000	B-BRAND
image	B-DEV
analyzer	I-DEV
(	O
GE	B-COM
Healthcare	I-COM
Bio-Science	I-COM
AB	I-COM
,	O
Uppsela	O
,	O
Sweden	O
)	O
.	O

Data	O
are	O
expressed	O
as	O
the	O
percentage	O
of	O
gel	O
area	O
compared	O
with	O
the	O
original	O
gel	O
size	O
.	O

Each	O
expansion	O
medium	O
was	O
supplemented	O
with	O
5	O
%	O
human	O
serum	O
type	O
AB	O
(	O
Biochrom	B-COM
AG	I-COM
,	O
Berlin	O
,	O
Germany	O
)	O
and	O
1000	O
IU/ml	O
of	O
IL-2	O
(	O
Proleukin	B-BRAND
S	I-BRAND
,	O
Novartis	O
Pharma	I-COM
GmbH	I-COM
,	O
Nürnberg	O
,	O
Germany	O
)	O
.	O

In	O
addition	O
,	O
NK	O
MACS	O
contained	O
2	O
%	O
NK	B-BRAND
MACS	I-BRAND
supplement	I-BRAND
®	I-BRAND
(	O
Miltenyi	B-COM
Biotec	I-COM
,	O
Bergisch	O
Gladbach	O
,	O
Germany	O
)	O
.	O

Hindlimb	O
ischemia	O
was	O
induced	O
by	O
ligating	O
the	O
right	O
femoral	O
artery	O
and	O
blood	O
flow	O
of	O
the	O
ischemic	O
limb	O
was	O
estimated	O
with	O
a	O
laser	B-DEV
Doppler	I-DEV
perfusion	I-DEV
imager	I-DEV
(	O
LDPI	B-DEV
;	O
Moor	B-COM
Instruments	I-COM
Ltd.	I-COM
,	I-COM
Devon	O
,	O
UK	O
)	O
to	O
confirm	O
the	O
angiogenic	O
effect	O
of	O
AM-Tg	O
mice	O
.	O

For	O
analysis	O
of	O
gel	O
electrophoresis	O
the	O
Blue	B-BRAND
Light	I-BRAND
Table	I-BRAND
and	O
Stain	B-BRAND
Clear	I-BRAND
G	I-BRAND
were	O
used	O
,	O
purchased	O
from	O
Serva	B-COM
Electrophoresis	I-COM
GmbH	I-COM
(	O
Heidelberg	O
,	O
Germany	O
)	O
.	O

All	O
oligonucleotides	O
were	O
synthesised	O
by	O
Eurofins	B-COM
Genomics	I-COM
(	O
Ebersberg	O
,	O
Germany	O
)	O
,	O
purchased	O
in	O
lyophilized	O
form	O
and	O
dissolved	O
in	O
nuclease-free	O
water	O
.	O

Light	O
emission	O
of	O
the	O
samples	O
were	O
measured	O
by	O
a	O
luminometer	B-DEV
(	O
Berthold	B-COM
Detection	I-COM
Systems	I-COM
,	O
GmbH	O
,	O
Germany	O
)	O
.	O

The	O
residual	O
activities	O
were	O
plotted	O
versus	O
urea	O
concentration	O
.	O

The	O
electrospray	O
ionization	O
(	O
ESI	O
)	O
mass	O
spectrometry	O
experiments	O
were	O
performed	O
on	O
an	O
Electronspray	B-BRAND
MS-LCQDeca	I-BRAND
(	O
Thermo	B-COM
Finnigan	I-COM
Ltd.	I-COM
,	O
Hertfordshire	O
,	O
UK	O
)	O
,	O
low	O
flow	O
,	O
and	O
mass	B-DEV
spectrometer	I-DEV
.	O

Samples	O
were	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
HPLC	O
grade	O
methanot/water	O
(	O
70:30	O
,	O
v/v	O
)	O
0.01	O
M	O
in	O
ammonium	O
acetate	O
.	O

The	O
binding	O
of	O
the	O
secondary	O
antibody	O
was	O
detected	O
with	O
peroxidase-labelled	O
sheep	O
anti-human	O
IgG	O
(	O
The	B-COM
Binding	I-COM
Site	I-COM
Ltd	I-COM
,	O
Birmingham	O
UK	O
)	O
.	O

Serum	O
IgG	O
titres	O
from	O
individual	O
animals	O
were	O
calculated	O
from	O
the	O
standard	O
curve	O
as	O
mg	O
of	O
specific	O
IgG	O
per	O
mL	O
serum	O
,	O
using	O
Titretek	B-BRAND
software	B-DEV
from	O
which	O
geometric	O
mean	O
titres	O
(	O
GMT	O
)	O
and	O
standard	O
errors	O
of	O
the	O
mean	O
(	O
sem	O
)	O
were	O
determined	O
per	O
treatment	O
group	O
.	O

Materials	O
CSA	O
(	O
Novartis	B-COM
Pharma	I-COM
,	O
AG	O
,	O
Basel	O
,	O
Switzerland	O
)	O
,	O
Indo	O
(	O
European	B-COM
Egyptian	I-COM
Pharmaceutical	I-COM
Industries	I-COM
,	O
Alexandria	O
,	O
Egypt	O
)	O
,	O
cremophor	O
EL	O
(	O
Sigma-Aldrich	B-COM
,	O
MO	O
,	O
USA	O
)	O
and	O
thiopental	O
sodium	O
(	O
Biochemie	B-COM
GmbH	I-COM
,	O
Vienna	O
,	O
Austria	O
)	O
were	O
purchased	O
from	O
commercial	O
vendors	O
.	O

Data	O
processing	O
was	O
carried	O
out	O
using	O
Proteome	B-BRAND
Discoverer	I-BRAND
1.4	I-BRAND
(	O
Thermo	B-COM
Scientific	I-COM
)	O
,	O
and	O
database	O
searching	O
was	O
conducted	O
on	O
an	O
inhouse	O
installation	O
of	O
Mascot	B-BRAND
Server	I-BRAND
2.5	I-BRAND
(	O
Matrix	B-COM
Science	I-COM
Ltd.	I-COM
;	O
London	O
,	O
United	O
Kingdom	O
)	O
.	O

Mascot	O
settings	O
were	O
as	O
follows	O
:	O
precursor	O
mass	O
tolerance	O
,	O
3	O
ppm	O
;	O
fragment	O
mass	O
tolerance	O
,	O
0.5	O
Da	O
;	O
maximum	O
missed	O
cleavage	O
sites	O
,	O
2	O
;	O
ion	O
score	O
or	O
expected	O
cut-off	O
,	O
20	O
;	O
significance	O
threshold	O
,	O
P	O
<	O
0.01	O
;	O
cysteine	O
carbamidomethylation	O
(	O
CAM-C	O
)	O
was	O
chosen	O
as	O
fixed	O
posttranslational	O
modification	O
(	O
PTM	O
)	O
,	O
whereas	O
methionine	O
oxidation	O
(	O
Met-Ox	O
)	O
was	O
chosen	O
as	O
variable	O
PTM	O
.	O

On	O
day	O
2	O
,	O
samples	O
were	O
submerged	O
in	O
Tissue-Tek	B-BRAND
OCT	I-BRAND
compound	O
(	O
Sakura	B-COM
Finetek	I-COM
,	O
Torrance	O
,	O
CA	O
)	O
and	O
frozen	O
at	O
À	O
80	O
°C	O
before	O
being	O
sectioned	O
at	O
12	O
mm	O
on	O
a	O
Microm	B-BRAND
HM	I-BRAND
500	I-BRAND
M	I-BRAND
cryostat	I-BRAND
(	O
Microm	B-COM
International	I-COM
GmbH	I-COM
,	O
Walldorf	O
,	O
Germany	O
)	O
.	O

Sections	O
were	O
collected	O
on	O
SuperFrost	B-BRAND
Plus	I-BRAND
slides	I-BRAND
(	O
Fisher	B-COM
Scientific	I-COM
)	O
and	O
dried	O
for	O
30	O
min	O
at	O
RT	O
,	O
then	O
fixed	O
in	O
4	O
%	O
paraformaldehyde	O
in	O
.03	O
%	O
PBT	O
at	O
RT	O
for	O
30	O
min	O
.	O

From	O
the	O
residue	O
,	O
10	O
mg	O
were	O
used	O
for	O
NMR	O
analysis	O
(	O
1	O
H	O
and	O
13	O
C	O
NMR	O
)	O
(	O
Advance	B-BRAND
500	I-BRAND
,	O
Bruker	B-COM
Biospin	I-COM
GmbH	I-COM
,	O
Rheinstetten	O
,	O
Germany	O
)	O
.	O

Kinetic	O
analysis	O
of	O
α-and	O
β-ionone	O
conversion	O
For	O
the	O
estimation	O
of	O
the	O
kinetic	O
constants	O
,	O
increasing	O
concentrations	O
of	O
the	O
ionones	O
(	O
0-150	O
μM	O
)	O
with	O
fixed	O
concentrations	O
of	O
CYP109D1	O
(	O
1	O
μM	O
)	O
,	O
Adx	O
(	O
10	O
μM	O
)	O
,	O
and	O
AdR	O
(	O
1	O
μM	O
)	O
were	O
used	O
.	O

To	O
visualize	O
and	O
capture	O
the	O
tooth	O
image	O
,	O
white	O
light	O
from	O
a	O
special	O
arc	B-DEV
lamp	I-DEV
Philips	B-COM
bv	I-COM
,	O
Eindhoven	O
,	O
the	O
Netherlands	O
based	O
on	O
xenon	O
technology	O
was	O
filtered	O
through	O
a	O
blue-transmitting	B-DEV
bandpass	I-DEV
filter	I-DEV
Philips	B-COM
bv	I-COM
with	O
a	O
peak	O
intensity	O
of	O
370	O
nm	O
and	O
a	O
bandwidth	O
of	O
80	O
nm	O
,	O
to	O
illuminate	O
the	O
tooth	O
with	O
a	O
blue-violet	O
light	O
with	O
an	O
intensity	O
of	O
13	O
mW/cm	O
2	O
.	O

Images	O
were	O
obtained	O
by	O
a	O
BZ-8000	B-BRAND
fluorescence	O
microscope	I-DEV
(	O
Keyence	B-COM
Deutschland	I-COM
GmbH	I-COM
,	O
Germany	O
)	O
and	O
analysed	O
via	O
CellProfiler	B-BRAND
2.0	I-BRAND
r11710	I-BRAND
(	O
Broad	B-COM
Institute	I-COM
of	I-COM
MIT	I-COM
and	I-COM
Harvard	I-COM
,	O
USA	O
)	O
.	O

,	O
Canada	O
)	O
and	O
an	O
AlphaGUARD	B-BRAND
PQ2000Pro	I-BRAND
radon	I-BRAND
monitor	I-BRAND
(	O
Saphymo	B-COM
Gmbh	I-COM
,	O
Germany	O
)	O
as	O
a	O
reference	O
were	O
used	O
.	O

The	O
grab	O
sampling	O
method	O
using	O
Lucas	B-DEV
scintillation	I-DEV
cells	I-DEV
(	O
1	O
dm	O
3	O
Lucas	O
covered	O
by	O
ZnS	O
(	O
Ag	O
)	O
,	O
M	B-COM
EV	I-COM
Ltd.	O
,	O
Hungary	O
)	O
and	O
an	O
EMI	B-DEV
photomultiplier	I-DEV
were	O
used	O
to	O
determine	O
the	O
radon	O
concentrations	O
.	O

Materials	O
and	O
methods	O
Activated	O
sludge	O
samples	O
and	O
DNA	O
extraction	O
Activated	O
sludge	O
samples	O
were	O
collected	O
from	O
one	O
industria	O
l	O
WWTP	O
(	O
plant	O
A	O
)	O
and	O
seven	O
domestic	O
WWTPs	O
(	O
plants	O
B-H	O
)	O
located	O
in	O
Japan	O
(	O
Table	O
SMTotal	O
DNA	O
of	O
each	O
activated	O
sludge	O
sample	O
was	O
extracted	O
as	O
follows	O
:	O
each	O
activated	O
sludge	O
sample	O
was	O
centrifuged	O
at	O
4000	O
g	O
for	O
15	O
min	O
and	O
the	O
total	O
DNA	O
of	O
each	O
sample	O
was	O
extracted	O
from	O
250	O
mg	O
of	O
the	O
wet	O
precipita	O
te	O
using	O
a	O
NucleoSpin	B-BRAND
Soil	I-BRAND
kit	I-BRAND
(	O
MACHEREY-NAG	B-COM
EL	I-COM
GmbH	I-COM
,	O
KG	O
,	O
Germany	O
)	O
.	O

The	O
DNA	O
extract	O
was	O
cleaned	O
up	O
using	O
a	O
NucleoSpin	B-BRAND
gDNA	I-BRAND
Clean-up	I-BRAND
kit	I-BRAND
(	O
MACHEREY-NAGEL	B-COM
GmbH	I-COM
,	O
KG	O
)	O
.	O

The	O
jugular	O
vein	O
was	O
cannulated	O
and	O
the	O
cannulae	O
were	O
subsequently	O
kept	O
patent	O
using	O
a	O
saline	O
solution	O
(	O
50	O
units	O
of	O
heparin	O
per	O
milliliter	O
saline	O
,	O
Multiparin	B-BRAND
,	O
CP	B-COM
Pharmaceuticals	I-COM
Ltd	I-COM
,	O
Wrexham	O
,	O
UK	O
+300	O
mg	O
crystapen	O
antibiotic	O
per	O
500	O
ml	O
,	O
Biochemie	B-COM
GmbH	I-COM
,	O
Tirol	O
,	O
Austria	O
)	O
.	O


,	O
Hitchin	O
,	O
Hertfordshire	O
,	O
UK	O
;	O
EGFR	O
Y845	O
and	O
c-Src	O
Y418	O
were	O
from	O
BioSource	B-COM
Europe	I-COM
S.A.	O
(	O
Fleures	O
,	O
Belgium	O
)	O
,	O
ErbB2	O
Y1248	O
was	O
from	O
Upstate	B-COM
Biotechnology	I-COM
(	O
Lake	O
Placid	O
,	O
NY	O
)	O
;	O
and	O
-	O
actin	O
was	O
from	O
Sigma-Aldrich	B-COM
.	O

The	O
absorbance	O
was	O
read	O
at	O
540	O
nm	O
with	O
a	O
EZ	B-BRAND
400	I-BRAND
microplate	I-BRAND
reader	I-BRAND
(	O
Biochrom	B-COM
Ltd	I-COM
,	O
Cambridge	O
,	O
UK	O
)	O
and	O
the	O
optical	O
densities	O
used	O
to	O
determine	O
cell	O
viability	O
and	O
to	O
calculate	O
IC	O
50	O
.	O

Cubes	O
of	O
cellular	O
rigid	O
polyurethane	B-DEV
foam	I-DEV
(	O
Sawbones	B-COM
Europe	I-COM
AB	I-COM
,	O
Malmö	O
,	O
Sweden	O
)	O
50	O
×	O
50	O
mm	O
with	O
three	O
different	O
qualities	O
were	O
used	O
to	O
simulate	O
``	O
severely	O
osteoporotic	O
bone	O
''	O
(	O
160	O
kg/m	O
-3	O
)	O
,	O
``	O
mildly	O
osteoporotic	O
bone	O
''	O
(	O
240	O
kg/m	O
-3	O
)	O
,	O
and	O
``	O
normal	O
bone	O
''	O
(	O
320	O
kg/m	O
-3	O
)	O
.	O

Subsequently	O
,	O
CD4	B-DEV
‡	I-DEV
T	I-DEV
cells	I-DEV
were	O
separated	O
by	O
high	O
gradient	O
magnetic	O
sorting	O
using	O
the	O
Variomacs	B-BRAND
technique	I-BRAND
(	O
Miltenyi	B-COM
Biotec	I-COM
GmbH	I-COM
,	O
Bergisch-Gladbach	O
,	O
Germany	O
)	O
.	O

PBMC	O
were	O
incubated	O
with	O
saturating	O
concentrations	O
of	O
CD4	O
mAb	O
conjugated	O
with	O
paramagnetic	B-DEV
microbeads	I-DEV
for	O
15	O
min	O
on	O
ice	O
,	O
washed	O
in	O
PBS	O
supplemented	O
with	O
0.5	O
%	O
bovine	O
serum	O
albumin	O
,	O
and	O
5	O
mM	O
EDTA	O
and	O
separated	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
cross-sectional	O
images	O
obtained	O
by	O
pQCT	O
were	O
analyzed	O
using	O
BonAlyse	B-BRAND
software	I-BRAND
(	O
BonAlyse	B-COM
Oy	I-COM
,	O
Jyvaskyla	O
,	O
Finland	O
)	O
,	O
which	O
automatically	O
identifies	O
cortical	O
and	O
trabecular	O
bone	O
and	O
assesses	O
its	O
density	O
.	O

AcKnOwLEdgEMEnt	O
Alexander	O
geurts	O
was	O
supported	O
by	O
an	O
unrestricted	O
grant	O
from	O
Ipsen	B-COM
Farmaceutica	I-COM
BV	I-COM
in	O
the	O
netherlands	O
.	O

REFEREncES	O
ELISA	O
and	O
multiplex	O
analyses	O
Serum	O
levels	O
of	O
the	O
following	O
endothelial	O
markers	O
were	O
measured	O
by	O
ELISA	B-BRAND
:	B-BRAND
sCD141	I-BRAND
(	O
soluble	B-COM
thrombomodulin	I-COM
,	O
Diaclone	O
,	O
Besançone	O
,	O
France	O
)	O
,	O
suppressor	O
of	O
tumorigenicity-2	O
(	O
ST2	O
)	O
,	O
interleukin-33	O
(	O
R&D	B-COM
Systems	I-COM
Europe	I-COM
Ltd	I-COM
,	O
Abingdon	O
,	O
UK	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
R&D	B-COM
Systems	I-COM
)	O
.	O

Briefly	O
,	O
A172	O
and	O
T98G	O
glioblastoma	O
cells	O
and	O
primary-cultured	O
astrocytes	O
were	O
cultured	O
in	O
different	O
96-well	O
plates	O
(	O
Greiner	B-COM
Bio-One	O
GmbH	O
,	O
Frickenhausen	O
,	O
Germany	O
)	O
at	O
a	O
density	O
of	O
5x10	O
3	O
cells	O
/	O
well	O
.	O

After	O
identifying	O
the	O
origin	O
of	O
the	O
occluded	O
mesenteric	O
artery	O
,	O
an	O
attempt	O
was	O
made	O
to	O
cross	O
the	O
occlusion	O
from	O
below	O
,	O
using	O
a	O
Simonds	O
shape	O
catheter	O
and	O
0.035	O
guide	O
wire	O
(	O
Terumo	O
Sweden	O
AB	O
,	O
Sweden	O
)	O
.	O

If	O
this	O
failed	O
,	O
an	O
attempt	O
was	O
made	O
at	O
using	O
the	O
same	O
technique	O
from	O
the	O
arm	O
with	O
a	O
4F	B-DEV
Headhunter	I-DEV
catheter	I-DEV
(	O
COOK	O
Europe	O
,	O
Bjaereskov	O
,	O
Denmark	O
)	O
and	O
0.035	O
guide	O
wire	O
.	O

DNA	O
Extraction	O
Paraffin-embedded	O
tissues	O
were	O
macrodissected	O
based	O
on	O
hematoxylin	O
and	O
eosin	O
staining	O
evaluations	O
to	O
ensure	O
a	O
minimum	O
of	O
75	O
%	O
of	O
tumor	O
cells	O
.	O

6,7	O
Corresponding	O
slides	O
were	O
digested	O
using	O
proteinase	O
K	O
(	O
Roche	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
overnight	O
before	O
DNA	O
extraction	O
using	O
standard	O
methods	O
.	O

C-reactive	O
protein	O
was	O
measured	O
with	O
a	O
high-sensitivity	O
reagent	O
kit	O
(	O
CP	O
3847	O
,	O
Randox	B-COM
Laboratories	I-COM
Ltd	I-COM
,	O
Crumlin	O
,	O
United	O
Kingdom	O
)	O
.	O

Definitions	O
of	O
Outcome	O
Measures	O
Patients	O
were	O
followed	O
up	O
by	O
telephone	O
interviews	O
and	O
by	O
medical	O
records	O
at	O
1	O
year	O
.	O

Group	O
D	O
received	O
pentobarbitone	O
(	O
Nembutal	O
;	O
Abbot	B-COM
BV	I-COM
,	O
Amstelveen	O
,	O
The	O
Netherlands	O
)	O
diluted	O
to	O
15	O
mg/ml	O
injected	O
into	O
an	O
ear	O
vein	O
.	O

Color	O
Fillet	O
surface	O
color	O
(	O
CIE	O
Lab	O
)	O
was	O
assessed	O
on	O
all	O
the	O
fillets	O
in	O
the	O
design	O
(	O
n	O
=	O
80	O
)	O
by	O
a	O
digital	B-DEV
photo	I-DEV
imaging	I-DEV
color-measuring	I-DEV
system	I-DEV
(	O
DigiEye	B-BRAND
full	I-BRAND
system	I-BRAND
,	O
VeriVide	B-COM
Ltd.	I-COM
,	O
Leicester	O
,	O
UK	O
)	O
after	O
7	O
d	O
of	O
storage	O
.	O

The	O
fillets	O
were	O
placed	O
in	O
a	O
standardized	O
lightbox	O
with	O
daylight	O
(	O
6400	O
K	O
)	O
and	O
photographed	O
with	O
a	O
calibrated	O
digital	B-DEV
camera	I-DEV
(	O
Nikon	B-BRAND
D80	I-BRAND
,	O
35	O
mm	O
lens	O
,	O
Nikon	B-COM
Corp.	I-COM
,	O
Japan	O
)	O
.	O

NE	O
tissue	O
content	O
was	O
measured	O
using	O
a	O
NE	B-BRAND
research	I-BRAND
ELISA	I-BRAND
kit	I-BRAND
(	O
Demeditec	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Kiel	O
,	O
Germany	O
)	O
,	O
fol-lowing	O
the	O
manufacturer	O
's	O
instructions	O
.	O

The	O
need	O
for	O
electrocauterization	O
(	O
Martin	B-BRAND
ME	I-BRAND
82	I-BRAND
,	O
KLS	B-COM
Martin	I-COM
Group	I-COM
,	O
Tuttlingen	O
,	O
Germany	O
)	O
and/or	O
for	O
suturing	O
(	O
Seralon	B-BRAND
5-0	I-BRAND
,	O
Serag	B-COM
Wiessner	I-COM
GmbH	I-COM
&	I-COM
Co.	I-COM
,	O
Naila	O
,	O
Germany	O
)	O
to	O
stop	O
the	O
bleeding	O
was	O
recorded	O
separately	O
.	O

Specific-IgE	O
Measurements	O
Serum	O
sIgE	O
levels	O
were	O
determined	O
by	O
a	O
screening	O
method	O
(	O
ImmunoCAP	O
,	O
Phadiatop	B-BRAND
Infant	I-BRAND
™	I-BRAND
,	O
Pharmacia	B-COM
Diagnostics	I-COM
AB	I-COM
,	O
Uppsala	O
,	O
Sweden	O
)	O
against	O
the	O
same	O
panel	O
of	O
inhalant	O
and	O
food	O
allergens	O
as	O
listed	O
above	O
for	O
SPT	O
.	O

Internalization	O
was	O
analyzed	O
using	O
a	O
LEICA	B-BRAND
TCS	I-BRAND
SP8	I-BRAND
confocal	I-BRAND
microscope	I-BRAND
and	O
the	O
corresponding	O
software	O
(	O
Leica	B-COM
Microsystems	I-COM
GmbH	I-COM
,	O
Wetzlar	O
,	O
Germany	O
)	O
.	O

Colorimetric	O
XTT	O
cell	O
proliferation	O
assay	O
The	O
cytotoxic	O
activity	O
of	O
425	O
(	O
scFv	O
)	O
-	O
ETA	O
′	O
against	O
three	O
different	O
RMS	O
cell	O
lines	O
(	O
RD	O
,	O
FL-OH1	O
and	O
TE-671	O
)	O
was	O
determined	O
using	O
a	O
cell	O
proliferation	O
assay	O
based	O
on	O
XTT	O
as	O
previously	O
described	O
(	O
Schiffer	O
et	O
al.	O
2013	O
)	O
.	O

One	O
microlitre	O
of	O
extracted	O
DNA	O
solution	O
was	O
added	O
to	O
the	O
PCR	O
mixture	O
containing	O
2.5	O
U	O
of	O
Dream	B-BRAND
Taq	I-BRAND
DNA	I-BRAND
polymerase	I-BRAND
(	O
Fermentas	B-COM
Life	I-COM
Technologies	I-COM
,	O
Helsingborg	O
Sweden	O
)	O
,	O
250	O
mM	O
dNTPs	O
,	O
0.8	O
mM	O
forward	O
primer	O
ITS1F	O
and	O
0.5	O
mM	O
reverse	O
primer	O
ITS4A	O
,	O
and	O
1	O
ml	O
of	O
BSA	O
(	O
Roche	B-COM
,	B-COM
Diagnostics	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
in	O
25	O
ml	O
of	O
1	O
¥	O
reaction	O
buffer	O
(	O
Clontech	B-COM
,	O
Mountain	O
View	O
,	O
USA	O
)	O
.	O

Serum	O
25	O
(	O
OH	O
)	O
D	O
3	O
and	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
were	O
analysed	O
using	O
chemoluminescence	O
on	O
a	O
Cobas	B-BRAND
e602	I-BRAND
unit	I-BRAND
(	O
Roche	B-COM
Diagnostics	I-COM
Scandinavia	I-COM
AB	I-COM
,	O
Bromma	O
,	O
Sweden	O
)	O
.	O

Calcium	O
levels	O
were	O
measured	O
on	O
a	O
KonelabTM	B-BRAND
PRIME	I-BRAND
30i	I-BRAND
equipment	O
(	O
Thermo	B-COM
Fischer	I-COM
Scientific	I-COM
Inc	I-COM
,	O
Waltham	O
,	O
MA	O
,	O
USA	O
)	O
.	O

G	O
(	O
Zimmer	B-COM
Surgical	I-COM
,	O
Dover	O
,	O
OH	O
,	O
USA	O
)	O
;	O
Refobacin	O
Ò	O
Bone	O
Cement	O
R40	O
(	O
Biomet	B-COM
)	O
;	O
Simplex	O
TM	O
P	O
with	O
Tobramycin	O
(	O
Stryker	B-COM
Orthopaedics	I-COM
,	O
Limerick	O
,	O
Ireland	O
)	O
;	O
SmartSet	B-BRAND
GHV	I-BRAND
Gentamicin	O
(	O
DePuy	B-COM
Ltd.	I-COM
,	O
Blackpool	O
,	O
UK	O
)	O
;	O
and	O
SmartSet	B-BRAND
GMV	I-BRAND
Gentamicin	O
(	O
DePuy	B-COM
Ltd.	I-COM
)	O
.	O

Peritoneal	O
Macrophages-Peritoneal	O
macrophages	O
from	O
C3H/HeN	B-BRAND
and	O
C3H/HeJ	B-BRAND
mice	B-DEV
(	O
Harlan	B-COM
Ltd.	I-COM
,	O
Oxon	O
,	O
UK	O
)	O
were	O
collected	O
by	O
lavage	O
4	O
days	O
after	O
intraperitoneal	O
injections	O
of	O
3	O
ml	O
of	O
3	O
%	O
thioglycollate	O
(	O
Difco	B-COM
,	O
Detroit	O
,	O
MI	O
)	O
.	O

The	O
England	O
Finders	O
were	O
positioned	O
in	O
Quadriperm	B-BRAND
culture	B-DEV
flasks	I-DEV
(	O
Greiner	B-COM
Bio-One	I-COM
GmbH	I-COM
,	O
Frickenhausen	O
,	O
Germany	O
)	O
in	O
which	O
cells	O
were	O
incubated	O
with	O
6	O
ml	O
of	O
Dulbecco	O
's	O
modified	O
Eagle	O
's	O
medium	O
(	O
DMEM	B-BRAND
cell	I-BRAND
culture	I-BRAND
;	O
Gibco-Invitrogen	B-COM
,	O
Paisley	O
,	O
UK	O
)	O
supplemented	O
with	O
10	O
%	O
fetal	O
calf	O
serum	O
,	O
100	O
U/ml	O
penicillin	O
,	O
100	O
mg/ml	O
streptomycin	O
,	O
and	O
2	O
mMol/ml	O
glutamine	O
(	O
all	O
from	O
Biochrom	B-COM
,	O
Berlin	O
,	O
Germany	O
)	O
at	O
37	O
C	O
in	O
a	O
humidified	O
atmosphere	O
of	O
5	O
%	O
CO	O
2	O
.	O

All	O
of	O
the	O
cements	O
were	O
tested	O
in	O
their	O
proprietary	O
forms	O
with	O
pre-mixed	O
gentamicin	O
and	O
also	O
with	O
the	O
addition	O
of	O
1	O
g	O
vancomycin	O
and	O
2	O
g	O
vancomycin	O
.	O

The	O
vancomycin	O
(	O
Alpharma	B-COM
Ltd	I-COM
,	O
Barnstaple	O
,	O
United	O
Kingdom	O
)	O
was	O
mixed	O
into	O
the	O
cement	O
polymer	O
as	O
a	O
powder	O
,	O
manually	O
using	O
a	O
metal	B-DEV
spatula	I-DEV
as	O
done	O
in	O
clinical	O
practice	O
,	O
prior	O
to	O
adding	O
the	O
monomer	O
.	O

The	O
PCR	O
products	O
were	O
analyzed	O
by	O
electrophoresis	O
in	O
a	O
1	O
%	O
low-melting-temperature	O
agarose	O
gel	O
and	O
subsequently	O
purified	O
by	O
using	O
a	O
QIAquick	B-BRAND
gel	B-DEV
extraction	I-DEV
kit	I-DEV
(	O
Qiagen	B-COM
Ltd.	I-COM
,	O
Crawley	O
,	O
United	O
Kingdom	O
)	O
.	O

Purified	O
amplicons	O
were	O
sequenced	O
by	O
using	O
an	O
ABI	B-BRAND
PRISM	I-BRAND
BigDye	I-BRAND
terminator	I-BRAND
cycle	O
sequencing	O
ready	O
reaction	B-DEV
kit	I-DEV
(	O
version	O
3.0	O
)	O
and	O
an	O
ABI	B-BRAND
PRISM	I-BRAND
3100	I-BRAND
genetic	B-DEV
analyzer	I-DEV
(	O
Applied	B-COM
Biosystems	I-COM
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Samples	O
were	O
analysed	O
using	O
a	O
PDZ	B-BRAND
Europa	I-BRAND
ANCA-GSL	I-BRAND
elemental	B-DEV
analyzer	I-DEV
interfaced	O
to	O
a	O
PDZ	B-BRAND
Europa	I-BRAND
20-20	I-BRAND
isotope	B-DEV
ratio	I-DEV
mass	I-DEV
spectrometer	I-DEV
(	O
Sercon	B-COM
Ltd.	I-COM
,	O
Cheshire	O
,	O
UK	O
)	O
.	O

The	O
samples	O
were	O
reacted	O
with	O
chromium	O
oxide	O
and	O
silvered	O
copper	O
oxide	O
at	O
1000	O
°C	O
,	O
the	O
oxides	O
were	O
removed	O
,	O
and	O
N	O
2	O
and	O
CO	O
2	O
were	O
trapped	O
and	O
separated	O
on	O
a	O
Carosieve	O
GC	O
column	O
before	O
the	O
IRMS	O
.	O

Mycobacteria	O
were	O
identified	O
by	O
16S	O
rRNA	O
gene	O
sequence	O
analysis	O
,	O
as	O
previously	O
described	O
(	O
18	O
)	O
and	O
analyzed	O
using	O
SmartGene	B-BRAND
IDNS	I-BRAND
software	B-DEV
(	O
SmartGene	B-COM
GmbH	I-COM
,	O
Zug	O
,	O
Switzerland	O
)	O
.	O


Mycobacterium	O
tuberculosis	O
clinical	O
isolates	O
were	O
analyzed	O
for	O
antibiotic	O
resistance	O
mutations	O
by	O
DNA	O
sequencing	O
.	O

HR	O
was	O
recorded	O
continuously	O
during	O
the	O
test	O
by	O
Team2	B-BRAND
Pro	I-BRAND
(	O
Polar	B-COM
Electro	I-COM
Oy	I-COM
,	O
Kempele	O
,	O
Finland	O
)	O
.	O

Statistical	O
analyses	O
Statistical	O
analyses	O
were	O
performed	O
using	O
IBM	B-BRAND
SPSS	I-BRAND
v.	O
20.0	O
(	O
SPSS	B-COM
,	O
Chicago	O
,	O
USA	O
)	O
.	O

Labelling	O
efficiency	O
was	O
measured	O
using	O
instant	O
thin	O
layer	O
chromatography	O
strips	O
(	O
ITLC-SA	B-BRAND
)	O
(	O
Varian	B-COM
Medical	I-COM
Systems	I-COM
UK	I-COM
,	O
Ltd.	O
,	O
Crawley	O
,	O
UK	O
)	O
with	O
a	O
mobile	O
phase	O
of	O
0.1	O
M	O
citrate	O
buffer	O
,	O
pH	O
5	O
and	O
analysed	O
using	O
a	O
gamma	B-DEV
ray	I-DEV
TLC	I-DEV
scanner	I-DEV
(	O
Lablogic	B-COM
,	O
UK	O
)	O
.	O

Microdialysis	B-DEV
pumps	I-DEV
(	O
CMA	B-BRAND
106	I-BRAND
;	O
CMA	B-COM
Microdialysis	I-COM
AB	I-COM
,	O
Solna	O
,	O
Sweden	O
)	O
were	O
used	O
at	O
a	O
constant	O
flow	O
rate	O
of	O
0.3	O
ml/min	O
.	O

The	O
inlet	O
tube	O
was	O
connected	O
to	O
a	O
zero-air	B-DEV
generator	I-DEV
(	O
Peak	B-COM
Scientific	I-COM
)	O
and	O
the	O
outlet	O
to	O
the	O
PTR-ToFMS	B-BRAND
(	O
8000	O
,	O
Ionicon	B-COM
Analitic	I-COM
GmbH	I-COM
,	O
Innsbruck	O
,	O
Austria	O
)	O
.	O

Care	O
was	O
taken	O
to	O
maintain	O
constant	O
temperature	O
and	O
humidity	O
during	O
measurements	O
as	O
chemical	O
reactions	O
are	O
very	O
sensitive	O
to	O
changes	O
of	O
such	O
parameters	O
(	O
Mancuso	O
et	O
al.	O
,	O
2015	O
)	O
.	O

The	O
plasma	O
FFA	O
concentration	O
was	O
measured	O
spectrophotometrically	O
(	O
Wako	B-COM
Chemicals	I-COM
Gmbh	I-COM
,	O
Neuss	O
,	O
Germany	O
)	O
.	O

The	O
3	O
-	O
[	O
3	O
H	O
]-	O
glucose-specific	O
activity	O
was	O
measured	O
on	O
barium	O
hydroxide/zinc	O
sulfate-deproteinized	O
plasma	O
samples	O
.	O

NOV.	O
137	O
algorithm	O
was	O
implemented	O
as	O
part	O
of	O
the	O
program	B-DEV
package	I-DEV
SAGE	B-BRAND
(	O
Technoma	B-COM
GmbH	I-COM
,	O
Heidelberg	O
,	O
Germany	O
)	O
.	O


Quinones	O
were	O
extracted	O
and	O
analyzed	O
as	O
described	O
by	O
Auling	O
et	O
al.	O
(	O
3	O
)	O
.	O

Superfect	O
reagent	O
for	O
transfection	O
was	O
purchased	O
from	O
Qiagen	O
(	O
Qiagen	B-COM
GmbH	I-COM
,	O
Germany	O
)	O
.	O

iNOS	O
,	O
COX-2	O
,	O
TNF-α	O
,	O
IL-6	O
,	O
and	O
β-actin	B-BRAND
oligonucleotide	I-BRAND
primers	O
were	O
purchased	O
from	O
Bioneer	B-COM
(	O
Seoul	O
,	O
South	O
Korea	O
)	O
.	O

3	O
-	O
(	O
4,5-dimethylthiazol-2-yl	O
)	O
-2,5-Diphenyl-tetrazolium	O
bromide	O
(	O
MTT	O
)	O
,	O
aprotinin	O
,	O
leupeptin	O
,	O
phenylmethyl	O
sulfonylfluoride	O
(	O
PMSF	O
)	O
,	O
dithiothreitol	O
,	O
L-N6	O
-	O
(	O
1-iminoethyl	O
)	O
lysine	O
(	O
L-NIL	O
)	O
,	O
Triton	B-BRAND
X100	I-BRAND
,	O
Escherichia	O
coli	O
LPS	O
,	O
and	O
all	O
other	O
chemicals	O
were	O
purchased	O
from	O
Sigma	B-COM
Chemical	I-COM
Co.	I-COM
.	I-COM

Particle	O
size	O
measurement	O
and	O
emulsifying	O
activity	O
EPS	O
(	O
50	O
%	O
w/v	O
)	O
samples	O
dissolved	O
in	O
water	O
were	O
sonicated	O
for	O
5	O
min	O
,	O
and	O
the	O
particle	O
size	O
distributions	O
were	O
measured	O
by	O
laser	O
diffraction	O
(	O
Malvern	B-BRAND
Mastersizer	I-BRAND
2000	I-BRAND
,	O
Malvern	B-COM
Ltd	I-COM
,	O
Worcestershire	O
,	O
UK	O
)	O
.	O

Lyophilised	O
EPS	O
(	O
1	O
mg	O
)	O
was	O
dissolved	O
in	O
0.5	O
ml	O
deionised	O
water	O
,	O
heated	O
to	O
1008C	O
for	O
15	O
min	O
and	O
allowed	O
to	O
cool	O
to	O
room	O
temperature	O
(	O
25	O
+	O
28C	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
twelve	O
short-glassfibre-reinforced	O
(	O
SGFR	O
)	O
third-generation	O
composite	O
replicate	B-DEV
femurs	I-DEV
(	O
Sawbones	B-COM
Europe	I-COM
AB	I-COM
,	O
Malmö	O
,	O
Sweden	O
)	O
were	O
used	O
in	O
two	O
configurations	O
:	O
(	O
1	O
)	O
MDF	O
SP	O
:	O
singleplane	O
oblique	O
medial	O
closing-wedge	O
SCO	B-DEV
fixated	O
with	O
a	O
medial	O
angle	O
stable	O
implant	O
(	O
Tomofix	B-COM
,	O
Synthes	O
,	O
Bettlach	O
,	O
Swiss	O
)	O
and	O
(	O
2	O
)	O
MDF	O
BP	O
:	O
bi-plane	O
oblique	O
medial	O
closingwedge	O
SCO	O
(	O
Fig.	O
1	O
)	O
.	O

The	O
10	O
lL	O
reaction	O
mixture	O
prepared	O
in	O
a	O
LightCycler	B-BRAND
Ò	I-BRAND
480	I-BRAND
Multiwell	B-DEV
Plate	I-DEV
96	O
contained	O
LightCycler	B-BRAND
Ò	I-BRAND
480	I-BRAND
Probes	I-BRAND
Master	I-BRAND
reaction	B-DEV
mixture	I-DEV
(	O
Roche	B-COM
Diagnostics	I-COM
,	I-COM
GmbH	I-COM
,	O
Mannheim	O
,	O
Germany	O
)	O
,	O
2.5	O
pmol	O
of	O
each	O
primer	O
,	O
1	O
pmol	O
of	O
UPL	O
probe	O
,	O
4	O
mM	O
MgCl	O
2	O
,	O
and	O
1	O
lL	O
cDNA	O
.	O

PGI32	O
modElInG	O
thE	O
Cost-EffECtIvEnEss	O
of	O
thE	O
all	O
oRal	O
,	O
dIRECt-aCtInG	O
antIvIRal	O
REGImEn	O
daClatasvIR	O
Plus	O
sofosBuvIR	O
In	O
PatIEnts	O
Co-InfECtEd	O
WIth	O
hEPatItIs	O
C	O
vIRus	O
(	O
hCv	O
)	O
and	O
hIv	O
McEwan	O
P	O
1	O
,	O
Ward	O
T	O
1	O
,	O
Webster	O
S	O
1	O
,	O
Kalsekar	O
A	O
2	O
,	O
Brenner	O
M	O
3	O
,	O
Yuan	O
Y	O
2	O
1	O
Health	B-COM
Economics	I-COM
and	I-COM
Outcomes	I-COM
Research	I-COM
Ltd	I-COM
,	O
Monmouth	O
,	O
UK	O
,	O
2	O
Bristol-Myers	B-COM
Squibb	I-COM
Pharmaceuticals	I-COM
Ltd	I-COM
,	O
Princeton	O
,	O
NJ	O
,	O
USA	O
,	O
3	O
Bristol-Myers	B-COM
Squibb	I-COM
Pharmaceuticals	I-COM
Ltd	I-COM
,	O
Uxbridge	O
,	O
UK	O
objeCtives	O
:	O
Compared	O
to	O
infection	O
with	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
alone	O
,	O
patients	O
co-infected	O
with	O
HIV	O
have	O
faster	O
disease	O
progression	O
,	O
decreased	O
quality	O
of	O
life	O
and	O
increased	O
rates	O
of	O
mortality	O
.	O


